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Abstract
A randomised, double-blind, parallel-group trial to assess
mercaptopurine versus placebo to prevent or delay
recurrence of Crohn’s disease following surgical
resection (TOPPIC)
Jack Satsangi,1* Nicholas A Kennedy,1,2,3 Craig Mowat,4 Ian Arnott,5
Catriona Keerie,6 Steff Lewis6 and Holly Ennis6 on behalf of the TOPPIC
Collaborators Group
1Gastrointestinal Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh,
Edinburgh, UK
2Department of Gastroenterology, Royal Devon and Exeter Hospital, Exeter, UK
3School of Medicine, University of Exeter, Exeter, UK
4Gastrointestinal Unit, Ninewells Hospital, Dundee, UK
5Gastrointestinal Unit, Western General Hospital, Edinburgh, UK
6Edinburgh Clinical Trials Unit, Usher Institute of Population Health Sciences and Informatics,
University of Edinburgh, Edinburgh, UK
*Corresponding author J.Satsangi@ed.ac.uk
Background: Crohn’s disease (CD) is a chronic, relapsing, inflammatory bowel disease. Up to 65% of patients
with CD require an operation to control the disease within 10 years. Both endoscopic and clinical recurrence
is common within 2 years of operation, with re-operation rates cumulating at 5% of patients per year.
Objectives: This study assessed if the use of mercaptopurine (MP) can prevent or delay postoperative
recurrence in CD.
Design: An individually randomised, multicentre, double-blind, placebo-controlled trial with follow-up at
6, 13, 31, 49, 67, 85, 103, 121, 139 and 157 weeks.
Setting: Twenty-nine tertiary referral hospitals in the UK.
Participants: Those aged ≥ 16 years in Scotland (or aged ≥ 18 years in England and Wales) with a
histologically confirmed diagnosis of CD (according to the Lennard-Jones criteria) and surgical intervention
≤ 3 months prior to randomisation to remove all observable disease at ileocolonic or small bowel
resections. Patients were excluded if they had a known intolerance of or hypersensitivity to thiopurines;
were known to require further surgery; underwent strictureplasty alone; had a stoma; or had an active or
untreated malignancy or absent thiopurine S-methyltransferase (TPMT) activity. Prior to randomisation any
postoperative infections were fully treated and existing treatments for CD were stopped.
Intervention: Daily oral dose of MP or placebo, with dose adjusted according to body weight (kg) and
TPMT status. Blood samples for genetic and serological analysis were taken at randomisation with
additional blood and stool samples collected at weeks 0, 13, 49, 103 and 157 for central analysis of drug
metabolite and faecal calprotectin levels, with endoscopic assessment at weeks 49 and 157.
Main outcome measures: The primary end point was clinical recurrence of CD (Crohn’s Disease Activity
Index score of > 150 points plus 100-point rise) and the need for anti-inflammatory rescue therapy or
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primary surgical intervention. Secondary end points included faecal calprotectin and thioguanine levels,
and assessment of endoscopic recurrence. The primary analysis was adjusted for baseline values of previous
treatment with MP and azathioprine, with the adjusted analysis considered to be the primary analysis.
Results: Between June 2008 and April 2012, 240 patients were enrolled and received at least one dose
of the study drug. A total of 128 (53%) participants were randomised to receive MP and 112 (47%) to
receive placebo. No randomised patients were excluded from the analysis. More patients achieved the
primary end point in the placebo group (n = 26, 23.2%) than in the MP group (n = 16, 12.5%), with an
adjusted p-value of 0.073 [hazard ratio (HR) 0.535, 95% confidence interval (CI) 0.27 to 1.06]. Of the
smokers on MP, 3 out of 29 (10.3%) had clinical recurrence versus 12 out of 26 (46.2%) on placebo,
demonstrating that MP was effective at preventing postoperative recurrence in smokers (HR 0.127,
95% CI 0.04 to 0.46) but not in non-smokers (HR 0.898, 95% CI 0.42 to 1.94). The proportion of patients
experiencing adverse events was similar in the treatment and placebo groups.
Limitations: There was a lower than anticipated primary event rate (12.5% in the treatment group vs.
23.2% in the placebo group, as opposed to expected rates of 30% vs. 50%).
Conclusions: The Trial Of Prevention of Post operative Crohn’s disease (TOPPIC) is the largest single,
double-blind trial assessing the use of thiopurines to prevent postoperative recurrence in CD. From the trial
itself, MP was not effective in reducing the frequency of clinical postoperative recurrence of CD overall, but
the data suggest that it has clinically meaningful effect among the subgroup of patients who continue to
smoke after surgery.
Future work: Exploratory analyses of possible predictors of disease recurrence using collected data
and samples.
Trial registration: Current Controlled Trials ISRCTN89489788 and EudraCT 2006-005800-15.
Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical
Research Council and National Institute for Health Research (NIHR) partnership, and will be published in
full in Efficacy and Mechanism Evaluation; Vol. 4, No. 4. See the NIHR Journals Library website for further
project information.
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Plain English summary
C rohn’s disease (CD) is a serious disease causing a swelling and ulceration of the gut wall. Most patientsare treated with medicines but, after 10 years, two out of three people with CD need an operation.
CD can often come back after an operation, and almost half of those who have one will need another one.
Several medicines have been tested to see if they help stop CD coming back after an operation.
Azathioprine and mercaptopurine (MP) are medicines called thiopurines that alter the way that the
immune system works. Over the last 10 years, they have become widely used for CD when it is not easily
treated with other medicines but is not serious enough to need an operation. They have also been tested
to see if they can stop CD coming back after an operation, but previous studies were relatively small and
did not look at all relevant measures, so there was a need for a large modern study to look at the role of
thiopurines again.
The Trial Of Prevention of Post operative Crohn’s disease (TOPPIC) was a double-blind, randomised
controlled trial done to find out whether the use of MP after an operation can prevent or delay CD coming
back. Following informed consent, 240 patients were recruited into the study between 2007 and 2012
and randomly got either a daily dose of MP or matching placebo for 36 months. Data and samples were
collected regularly during the study.
Mercaptopurine reduced how often CD came back after an operation only in smokers, who were also the
people most at risk of recurrence.
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Scientific summary
Background
Crohn’s disease (CD) is a debilitating condition of unknown cause in which there is inflammation of the wall
of the gut. This may result in diarrhoea, abdominal pain, weight loss, tiredness and feeling generally unwell.
The disease commonly affects young people, affecting education, employment and family life. Most patients
are first treated medically, but over the first 10 years of the condition up to 65% of patients will need an
operation to control the disease. Recurrence of CD following surgery is almost universal, most commonly
occurring at the anastomosis (join) between the two sections of bowel. In excess of 40% of these individuals
will need further surgery to again control the disease within 10 years. A number of medications have been
tested previously to prevent or delay the recurrence of CD. The 5-aminosalicylates drugs are ineffective and
nitroimidazole antibiotics have some effect but cannot be taken in the long term because of their side
effects. Azathioprine and mercaptopurine (MP) (collectively termed thiopurines) are drugs that alter the way
that the immune system responds. They are well established in the maintenance of steroid-induced remission
in CD. They have been tested to prevent the postoperative recurrence, but the studies have been flawed and
results mixed.
Objectives
The primary objective of this study was to determine definitively if MP could prevent or delay postoperative
clinical recurrence of CD when compared with placebo. Secondary objectives included determining if MP
could prevent or delay endoscopic recurrence of CD using the Rutgeerts scoring system, whether or not
endoscopic recurrence could predict clinical recurrence, the relationship between faecal calprotectin or
6-thioguanine nucleotide levels and clinical efficacy, and changes in self-rated quality-of-life scores.
Methods
This was a multicentre, parallel-group, double-blind, randomised controlled trial conducted in the UK
(29 sites). Patients were eligible for the trial if they were aged ≥ 16 years in Scotland and ≥ 18 years in
England and Wales, had an ileocolic or small bowel resection ≤ 3 months before randomisation during which
all observable disease was removed, and had a histologically confirmed diagnosis of CD (according to the
Lennard-Jones criteria). Patients were excluded if they had a known intolerance or hypersensitivity to
thiopurines, were known to require further surgery, underwent strictureplasty alone, had a stoma, had an
active or untreated malignancy, or had absent thiopurine S-methyltransferase (TPMT) activity. Prior to
randomisation, any postoperative infections were fully treated and existing treatments for CD were stopped.
Intervention
The intervention was randomisation to either a daily oral dose of MP or placebo, with dose adjustment
according to body weight (kg) and TPMT status. Following informed signed consent, patients were
allocated 1 : 1 to the trial intervention. All clinicians and the study staff involved in day-to-day trial
management and outcome assessment were blinded to the study allocation. Blood samples for genetic
and serological analysis were taken at randomisation with additional blood and stool samples collected at
weeks 0, 13, 49, 103 and 157 for central analysis of drug metabolite and faecal calprotectin levels, with
endoscopic assessment at weeks 49 and 157. All clinicians caring for patients and study staff involved in
day-to-day trial management and outcome assessment were blinded to study allocation.
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Main outcome measures
The primary end point was clinical recurrence of CD [Crohn’s Disease Activity Index (CDAI) score of
> 150 points plus 100-point rise] and the need for anti-inflammatory rescue therapy or primary surgical
intervention. We also looked at the secondary outcome of clinical recurrence defined by a CDAI score
of ≥ 150 points together with a 100-point rise in the CDAI score from baseline or anti-inflammatory
rescue therapy, or primary surgical intervention. In addition, we looked at endoscopic recurrence using
the Rutgeerts scoring system and Crohn’s Disease Endoscopic Index of Severity (CDEIS) score, faecal
calprotectin levels, thioguanine (TGN) levels and changes in self-rated quality-of-life scores using the
Inflammatory Bowel Disease Questionnaire (IBDQ) and EuroQol-5 Dimensions (EQ-5D).
All analyses were intention to treat. The primary outcome variable was postoperative recurrence of CD and its
timing if it recurred. Analysis was intention to treat and based on the application of the Cox proportional
hazards model. The primary analysis included terms for treatment, the variables on which the randomisation
was stratified (smoking status and recruitment site) and adjusted for baseline values of previous treatment
with MP and previous treatment with azathioprine. The adjusted analysis was considered to be the primary
analysis of the primary outcome. Adjusted Cox proportional hazard ratios (HRs) were presented as the
comparison of MP versus placebo, with a HR of < 1 indicating a treatment effect in favour of MP.
The secondary outcome variable of clinical recurrence was analysed in the same manner as the primary
outcome. For both primary and secondary outcomes, the adjusted analysis was considered the primary
analysis. Endoscopic recurrence using both the Rutgeerts and CDEIS scoring systems were summarised by time
and treatment group. Colonoscopy results at week 157 post randomisation (study visit 12) were compared
between the treatment groups using a chi-squared test. CDEIS scores at week 157 post randomisation were
compared between treatment groups using a t-test. Results of faecal calprotectin levels were summarised by
time and treatment group, both as a continuous measure and categorically. Faecal calprotectin and TGN
levels of the MP drug metabolite were incorporated separately into a Cox proportional hazards model as
time-varying covariates. Quality of life, as measured by the IBDQ, was analysed using a change from baseline
repeated measures analysis of covariance to evaluate the effect of treatment over time for the overall average
IBDQ score and also the overall total IBDQ score. Quality of life, as measured by the EQ-5D, was summarised
by treatment group across study visits. We also carried out prespecified subgroup analyses of the primary and
secondary outcomes to assess for a treatment effect in terms of thiopurine naivety, previous treatment with
infliximab or methotrexate, previous surgery, smoking status, duration of disease and age at diagnosis. The
interaction between subgroup and treatment was included in the Cox regression model to determine if the
treatment effect differed by subgroup. The same subgroups analysed for the primary and secondary outcomes
were also analysed with respect to colonoscopy results and CDEIS scores.
Results
Between June 2008 and April 2012, 240 patients were enrolled and received at least one dose of study
drug. A total of 128 (53%) participants were randomised to receive MP and 112 (47%) were randomised
to receive placebo. A protocol violation was recorded involving a participant who was prescribed a study
drug from the wrong treatment arm 6 weeks post randomisation; the error was reported and correct study
drug issued. The study was completed as planned with an extension to the originally proposed recruitment
period. No randomised patients were excluded from the analysis. More patients achieved the primary
end point in the placebo (n = 26, 23.2%) group than in the MP group (n = 16, 12.5%), with an adjusted
p-value of 0.073 [HR 0.535, 95% confidence interval (CI) 0.27 to 1.06]. Smokers were more likely to reach
the primary end point than non-smokers (HR 0.127, 95% CI 0.04 to 0.46 among smokers; HR 0.898,
95% CI 0.42 to 1.94 among non-smokers; p = 0.018). The proportion of patients experiencing adverse
events was similar in the treatment and placebo groups. Likewise, there was little difference in the
per-patient number of adverse events between the groups.
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At baseline prior to randomisation, 146 participants (60.8%) of the whole cohort were female and 55
(22.9%) participants of the whole cohort were smokers. There were no differences between participants at
randomisation in terms of weight, faecal calprotectin levels, or CDAI or IBDQ scores.
A total of 128 (53%) participants received MP and 112 (47%) received the placebo. A total of 104 (43.3%)
participants received trial medication for the full 3-year treatment period. Overall, the mean period of
treatment was 22.6 months (maximum treatment time possible: 36 months). In the MP group, the mean
treatment period was 23.4 months, compared with 21.8 months in the placebo group. Adherence to trial
protocol resulted in a dose reduction over the course of the study in 39.1% of participants on MP versus
16.1% on placebo. Consequently, 61 out of 102 patients on MP who had TGN levels measured at week 49
post randomisation were on subtherapeutic drug doses (< 235 pmol/8 × 108 red blood cell count). Trial
medication was stopped in 37.5% of participants on MP versus 42.9% of participants on placebo. The
reasons for discontinuation of trial medication were adverse events (58.8%), regular safety blood monitoring
results (13.2%), early withdrawal (15.4%), loss to follow-up (11.8%) and death (0.7%). Follow-up data were
not available for all participants for the following reasons: early withdrawal [21 participants (8.7%)], loss to
follow-up [16 participants (6.6%)] and death [one participant (0.4%)].
Clinical recurrence of CD occurred in 42 (17%) participants: 16 out of 128 (12.5%) on MP versus 26 out of
112 (23.2%) on placebo (HR 0.535, 95% CI 0.27 to 1.06; p= 0.073). Of the 42 who reached the primary end
point, 37 participants (88%) met the CDAI score trigger and had rescue therapy initiated, whereas five (12%)
met the CDAI score trigger and had both rescue therapy and primary surgical intervention.
In the entire study cohort, the incidence of clinical recurrence was higher in smokers than among non-smokers
[15/55 (27.3%) vs. 27/185 (14.6%); p = 0.018]. Among the smokers, 3 out of 29 on MP (10.3%) experience
clinical recurrence, compared with 12 out of 26 (46.2%) on placebo, demonstrating that MP was effective
at preventing postoperative recurrence in smokers (HR 0.127, 95% CI 0.04 to 0.46) but not in non-smokers
(HR 0.898, 95% CI 0.42 to 1.94). Other subgroup analyses assessing previous thiopurine exposure, prior
methotrexate use, prior infliximab use, previous surgery and age at diagnosis did not identify any differences
between the groups.
The overall number of clinical recurrence secondary outcomes (defined by a CDAI score rise, or rescue
therapy or surgery) was 34 (26.6%) in the treatment arm and 40 (35.7%) in the placebo arm, with an
adjusted p-value of 0.243 (HR 0.737, 95% CI 0.44 to 1.23). Subgroup analyses for the secondary outcomes
demonstrated no statistically significant differences between subgroups, with the exception of smokers.
The overall number of patients with endoscopic recurrence [defined as a Rutgeerts score of ≥ i2 (≥ 5 aphthous
lesions with normal mucosa between lesions, or skip areas of larger lesions or lesions confined to the ileocolonic
anastomosis) at week 157 post randomisation] was 29 (32.6%) in the treatment arm and 28 (38.9%) in the
placebo arm, with an adjusted p-value of 0.382 (odds ratio 0.66, 95% CI 0.26 to 1.67).
There were no significant differences in endoscopic recurrence, as defined by the Rutgeerts score, by treatment
group on subgroup analyses except in the thiopurine-naive group. CDEIS scores at visits 6 and 12 were higher
in the placebo group than in those allocated to MP, although this difference was not statistically significant.
Analysis of faecal calprotectin levels as a time-varying covariate indicated that, for every 100-µg/g increase
in faecal calprotectin, the hazard of reaching the primary end point increased by 17.7% (HR 1.177, 95% CI
1.082 to 1.282; p = 0.0002).
There was no statistically significant association between TGN concentrations and the primary end point
(HR 0.800, 95% CI 0.565 to 1.132; p = 0.207).
The statistical analysis of patient-reported outcome measures (as measured by IBDQ) showed no significant
difference between treatment and placebo groups across all study visits, the overall average across the
study as a whole, and for the total IBDQ score.
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Of 1747 reported adverse events, 355 (20.3%) were infections, of which only seven (0.4%) necessitated
hospitalisation. Higher rates of adverse event reporting were seen in the group of patients allocated to
placebo. The majority of adverse events were classed as either mild or moderate in severity [868 (91.6%) in
the MP group and 728 (91.1%) in the placebo group]. Adverse events caused discontinuation of treatment
in 80 patients overall (33%): 39 of the 128 (30%) patients in the MP group versus 41 of the 112 (36.6%)
patients in the placebo group. There were two cases of pancreatitis among the overall 1747 reported
adverse events (0.1%: one in the MP group and one in the placebo group) and four malignancies (0.2%:
three in the MP group and one in the placebo group): basal cell carcinoma, breast cancer and two cases of
lentigo maligna. One participant in the placebo group died of coronary heart disease.
There were 14 pregnancies reported during the course of the trial, with 12 normal children and maternal
outcomes. We observed one spontaneous abortion at approximately 21 weeks’ gestation and one congenital
anomaly (heart murmur, septal defect and hydrocephalus) in the infant of a patient in the placebo group.
Conclusions
The Trial Of Prevention of Post operative Crohn’s disease (TOPPIC) is the largest double-blind trial assessing
the use of thiopurines to prevent postoperative recurrence in CD. From the trial itself, MP was not effective in
reducing the frequency of clinical postoperative recurrence of CD overall, but the data suggest that it has
clinically meaningful effect among the subgroup of patients who continue to smoke after surgery.
Recommendations for research
The trial results raise the following questions:
1. What is the impact of smoking cessation in this population and what are the mechanisms of action of
smoking on increasing disease recurrence?
2. Could faecal calprotectin levels be used as a surrogate for endoscopic assessment?
3. What would the impact on the overall results have been if dosage levels had been informed throughout
the duration of the trial by the use of metabolite data, and could these data be used to deliver
treatment more effectively?
4. What are the factors behind an apparent discrepancy between clinical and endoscopic recurrence?
5. What are the long-term effects of MP in this population?
Future work
Exploratory analyses of possible predictors of disease recurrence using collected data and samples should be
undertaken. Biomarker discovery to stratify high-risk responders should also be researched in more detail.
Trial registration
This trial is registered as ISRCTN89489788 and EudraCT 2006-005800-15.
Funding
This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research
Council and National Institute for Health Research partnership.
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Chapter 1 Introduction
C rohn’s disease (CD) is a chronic, relapsing, inflammatory illness that can involve any part of thegastrointestinal tract, but most commonly involves the terminal ileum. The prevalence in northern
England has been estimated to be 144 per population of 100,000.1 The incidence among young people
in Scotland is the highest in the UK, and continues to rise.2 Although the mortality associated with
CD is low, there is significant morbidity, with serious effects on growth, development, education and
employment potential.
Crohn’s disease treatment
Treatment algorithms for the medical management of active CD have evolved very rapidly in recent years,
and the relative importance of thiopurines in induction of remission, and in maintenance, has been
re-evaluated since this study was first designed. Although steroids, biological therapies and combination
therapies (biologics used together with thiopurine agents) have an evidence basis for induction of remission,
a recent Cochrane review suggested that there was no place for monotherapy with thiopurine in induction
of remission.3
However, for patients entering medically induced remission, immunosuppression with azathioprine or
mercaptopurine (MP) is an effective maintenance strategy (odds ratio 3.17, number needed to treat 3.3
favouring 2 mg/kg azathioprine over placebo), offering an acceptable balance of efficacy, tolerability and
cost.4 The relative merits of monotherapy with thiopurines alone, anti-tumour necrosis factor alpha (TNF-α)
agents or combination regimes of thiopurines and biological agents remain contentious in this setting of
maintenance therapy.
Despite current medical therapy, up to 50% of patients have aggressive disease and require surgery within
5 years of diagnosis.5 Unfortunately, disease relapse rates are high within 2 years of surgery for both
endoscopic (72–98%) and clinical recurrence (37–70%).6 Re-operation rates cumulate at 5% of patients
per year.7
Evidence for postoperative use of thiopurines
The development of strategies to prevent or delay postoperative recurrence of CD is therefore of major
clinical importance; however, there is a paucity of evidence to support any particular drug strategy.8,9
The thiopurines, azathioprine and MP have an established role in inducing remission in CD and in the
maintenance of medically induced remission. These agents have historically been suggested in treatment
algorithms for patients at ‘high risk’ of postoperative relapse, but the evidence basis for their use in this
context, and indeed the evidence that clinical parameters may predict patients at ‘high risk’ of relapse,
is weak.7 A meta-analysis conducted by Jones et al.10 found that the efficacy data for thiopurines in the
postoperative setting were inconclusive and, aside from smoking, there were no consistent predictors
of postoperative relapse. A 2014 Cochrane review also concluded that, although there was evidence to
suggest that thiopurines may reduce endoscopic and clinical recurrence, the quality of evidence was
degraded by small numbers and flawed study designs.3 The value of thiopurine metabolites in this situation
is unknown.11 More recently, the role of biological therapies in postoperative prophylaxis has received
considerable attention. Following smaller randomised studies of infliximab in postoperative disease, the
recent Post-Operative Crohn’s Endoscopic Recurrence (POCER) study demonstrated that targeted escalation
of immune-modulatory therapy (thiopurines followed by adalimumab) in patients with early endoscopic
evidence of recurrence may delay subsequent endoscopic, although not clinical, recurrence.11–13
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Current practice
Currently no medical therapy is licensed to prevent postoperative recurrence in CD. As well as thiopurine
agents and anti-TNF-α agents, 5-aminosalicylates, corticosteroids and metronidazole have all been suggested,
but the evidence in favour of these drugs is weak and none is widely used in the UK.6 Postoperative
maintenance therapy with azathioprine or MP is more widely used and is included in a number of clinical
algorithms, but trial data from controlled trials available thus far have failed to demonstrate whether or
not this is an effective therapy. Existing studies have been underpowered, poorly designed or used an
inappropriate drug dose.6,14–19
For these reasons, we consider that evidence-based strategies to prevent postoperative recurrence are both
an unmet clinical need and a research priority.
Controversies in use of thiopurines in postoperative use
As we discussed in our recent review (see Jones et al.10), there are many unresolved controversies
associated with the use of thiopurines in the prevention of postoperative recurrence in CD, and this remains
contentious. The definition of recurrence itself, specifically the distinction between endoscopic, clinical and
surgical recurrence, the identification of high-risk individuals, the influence of pre-operative therapies on
responsiveness, and the relative merits of thiopurines compared with anti-TNF-α therapies are key issues;
however, no real evidence-based consensus has emerged.10 The European Crohn’s and Colitis Organisation
(ECCO) 2010 guidelines recommend their use postoperatively in ‘high-risk’ patients (defined as smokers
and those with previous intestinal surgery, penetrating disease, perianal disease or extensive small bowel
section).20 The British Society of Gastroenterology’s guidelines are more cautious in emphasising the weak
evidence base for risk factors in predicting disease recurrence (with the exception of smoking) and for the
use of thiopurines in this setting.8
The use of thiopurines by women, or the male partners of women, trying
to conceive or in pregnancy
With respect to safety, use in patients of childbearing age has been a key issue. When the trial commenced,
the published guidelines of both ECCO and the British Society of Gastroenterology supported the use of
thiopurines in inflammatory bowel disease (IBD) in women of childbearing potential and during pregnancy
on the grounds that the risk to the unborn child from disease activity appeared greater than continued
therapy. As part of the initial trial assessment by the Medicines and Healthcare products Regulatory Agency,
supporting documentation was reviewed and the inclusion of women of childbearing potential was approved
without inclusion criteria of agreement to the use of contraceptives. No comment was made for inclusion of
males who could potentially father a child while receiving MP. However, the sponsor, Trial Management
Group (TMG) and Trial Steering Committee (TSC) examined this position in more detail in 2010.
The TMG and TSC considered the evidence and decided not to exclude female patients who either were
planning to become pregnant or became pregnant, or male patients whose partners were planning to
become pregnant. The existing patient information sheets, however, were revised to detail the potential
risks to male patients. All enrolled male patients were also reconsented to the new information sheets and
consent forms. Pregnancy data were also included in the TSC and Data Monitoring Committee (DMC)
standard reports.
Since 2010, several large studies have been published examining thiopurine use for IBD during pregnancy,
which provided further support for the initial guidelines. The Cancers Et Surrisque Associé aux Maladies
inflammatoires intestinales En France (CESAME) study group examined 215 pregnancies in 204 women
and concluded that thiopurine use during pregnancy was not associated with increased risks, including an
INTRODUCTION
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increased risk of congenital abnormalities.21 This has been supported by the findings of two further studies
published in 2013 and 2014: Casanova et al.22 included a cohort of 187 pregnancies in participants using
thiopurines in IBD and found no evidence of an increased risk of complications, whereas Ban et al.23
included a cohort of 115 pregnancies in participants using thiopurines for CD and found no evidence of an
increased risk of major birth defects.
Potential health-care impact
The present study has an important potential impact on health care in terms of defining, with accuracy,
the clinical effectiveness of thiopurine therapy in the prevention of postoperative relapse. The data from the
study overall suggest that routine postoperative use of MP in all patients undergoing surgery is not justified as
a preventative measure. The subgroup analyses have helped identify smokers as the subgroup of individuals at
highest risk of relapse, and helped to demonstrate that this subgroup is most likely to benefit from thiopurine
therapy, thereby helping to target immunomodulatory therapy towards patients most likely to benefit. The
important secondary objectives allowed comparison of clinical and endoscopic recurrence rates, and analysis
of clinical as well as biomarker predictors of disease recurrence. Importantly, we have assessed age, the need
for previous surgery, previous thiopurine use and smoking as potential determinants of outcome.
Rationale for research
At present, there is no widely accepted algorithm or management plan in preventing postoperative relapse
of CD. Non-evidence-based algorithms have been widely used and the present study will allow clear
evidence to be defined in the largest study carried out in the use of thiopurine therapy.
The secondary objectives allowed comparison of clinical and endoscopic recurrence rates, and the effects
of thiopurine therapy on each of these aspects. The study design has also allowed examination of drug
safety, tolerability and adherence to therapy. The biomarkers in the study allow the relative predictive value
of faecal calprotectin levels in assessing recurrence to be defined, as well as the relationship between
thiopurine use and calprotectin levels. Quality of life was also measured in the present study. The primary
objective of this study was to assess if MP can prevent or delay postoperative recurrence in CD.
Study aims
The primary objective of the Trial Of Prevention of Post operative Crohn’s disease (TOPPIC) was to assess if
MP can prevent or delay postoperative recurrence of CD.
Secondary objectives included if MP can prevent or delay endoscopic evidence of recurrence and, finally,
whether or not endoscopic recurrence can predict clinical recurrence, whether or not faecal calprotectin
levels can be used as a non-invasive marker of disease recurrence that may remove the need for
colonoscopy in some patients, whether or not drug metabolite levels relate to clinical efficacy of MP,
and whether or not we can predict postoperative recurrence using clinical, genetic or serological data.
Development of TOPPIC
Development of TOPPIC was initiated in 2006 by a team of collaborators based in Scotland, with ethics
and clinical trial authorisation sought in 2007. The trial was extended throughout the UK in 2010 to
include collaborators from across England and Wales.
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Chapter 2 Methods
Trial design
This was a multicentre, parallel-group, double-blind, randomised controlled study conducted in the UK
(29 sites). Participants were allocated 1 : 1 to active treatment with MP or a matching placebo.
Following slower than projected recruitment in the first 24 months, the protocol was modified to reduce
the number of colonoscopies performed as part of the trial and to allow the inclusion of patients with a
previous history of malignancy, providing that they had been in remission for 5 years.
Participants
Participants were adults aged ≥ 16 years in Scotland (≥ 18 years in England and Wales) with a histologically
confirmed diagnosis of CD (according to the Lennard-Jones criteria) undergoing ileocolonic or small bowel
resection.24 Patients were approached ≤ 3 months after surgery during the perioperative period and,
following consent for screening, underwent a screening assessment consisting of a blood sample to check
thiopurine S-methyltransferase (TPMT) activity and a postoperative stool sample to exclude enteric infection.
One week prior to randomisation, eligible participants underwent standard safety blood tests (including
checks of liver function, haemoglobin levels, and white blood cell, neutrophil and platelet counts) in
addition to a urinary pregnancy test.
Inclusion and exclusion criteria are described in the following sections.
Inclusion criteria
l Aged ≥ 16 years in Scotland and ≥ 18 years in England and Wales.
l Established diagnosis of CD confirmed at recent resection.
l Ileocolonic or small bowel resection ≤ 3 months before screening.
l Had ≤ 100 cm of fixed small bowel resected in total; a previous ileocolonic resection was accepted.
l Able to start oral nutrition in the first 2 postoperative weeks.
l Normal or heterozygous TPMT (activity present or reduced, consistent with carrier status).
l Able to provide written informed consent prior to screening and comply with the requirements of the
study protocol.
l Not taking antibiotics at least 2 weeks prior to randomisation.
Exclusion criteria
l Pregnancy at baseline or breastfeeding.
l Known hypersensitivity or intolerance to MP.
l Pancreatitis associated with azathioprine.
l Receiving experimental treatment for CD ≤ 4 weeks prior to study entry.
l Known to require further surgery at study entry (i.e. for the removal of an abscess developing from the
primary surgery).
l Strictureplasty procedure alone (strictureplasty and resection procedure together will not be considered
an exclusion criterion).
l Presence of a stoma.
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Identifying participants
The study aimed to recruit and randomise from participating sites. Potentially eligible patients were
identified by clinicians and research/specialist nurses at sites following ileocolonic or small bowel resection.
Settings and locations where the data were collected
The study took place in the following tertiary referral hospitals in the UK: Western General Hospital,
Edinburgh; Aberdeen Royal Infirmary, Aberdeen; Ninewells Hospital, Dundee; Glasgow Royal Infirmary and
Stobhill Hospital, Glasgow; Royal Devon and Exeter Hospital, Exeter; University Hospital Coventry, Coventry;
Royal Liverpool University Hospital, Liverpool; Manchester Royal Infirmary, Manchester; Bristol Royal Infirmary,
Bristol; University College Hospital, Royal Free Hospital and Royal London Hospital, London; John Radcliffe
Hospital, Oxford; Salford Royal Hospital, Salford; Singleton Hospital, Swansea; Torbay Hospital, Torquay;
Southampton General Hospital, Southampton; County Durham and Darlington Memorial Hospitals, Durham
and Darlington; Royal Stoke University Hospital, Stoke-on-Trent; Queen’s Medical Centre, Nottingham;
St Mark’s Hospital, Harrow; Rotherham General Hospital, Rotherham; Queen Elizabeth Hospital, Birmingham;
and Raigmore Hospital, Inverness. Randomisation was open from May 2008 until June 2012 (a total of
49 months).
Interventions
The intervention was a random allocation to MP in 50-mg tablets or placebo in identical 50-mg tablets and
matched packaging supplied to sites by the manufacturer.
Outcomes
The primary study outcome was clinical recurrence of CD defined by a Crohn’s Disease Activity Index
(CDAI) score of ≥ 150 points together with a 100-point rise in the CDAI score from baseline, with the need
for anti-inflammatory rescue therapy or primary surgical intervention.25
The secondary study outcomes were as follows:
l clinical recurrence defined by a CDAI score of ≥ 150 points together with a 100-point rise in the CDAI
score from baseline, or anti-inflammatory rescue therapy or primary surgical intervention
l the need for a second operation to remove recurrent CD from the anastomotic site
l endoscopic recurrence using the Rutgeerts and Crohn’s Disease Endoscopic Index of Severity (CDEIS)
scoring systems26,27
l faecal calprotectin levels
l thioguanine (TGN) levels
l changes in self-rated quality-of-life scores.
Measurements
Following patient consent for screening, the trial screening process consisted of analysis of TPMT activity
and a postoperative stool sample to exclude enteric infection. One week prior to randomisation, eligible
participants underwent blood tests (including liver function tests, haemoglobin concentration tests, and
white blood cell, neutrophil and platelet counts) and a urinary pregnancy test. Patients returned to
designated clinics run by clinical teams for a baseline assessment including the CDAI, patient-reported
outcome measures including the Inflammatory Bowel Disease Questionnaire (IBDQ), a physical examination
METHODS
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and a blood sample for assay of drug metabolite level.28 Additional blood samples for genetic and
serological analysis were also taken, and results are reported separately.
Patients were randomised at baseline to receive either MP or placebo. MP was given at a dose of 1–1.5 mg/kg
of body weight, rounded to the nearest 25 mg as a single daily dose in the morning. Patients with low TPMT
activity were prescribed MP at half the normal dose. Treatment was on a maintenance basis for 3 years, with
the dose adjusted up or down for weight changes during the study.
Follow-up data were collected at 10 time points, at weeks 6, 13, 31, 49, 67, 85, 103, 121, 139 and 157
post randomisation. At each visit, the following data were collected: CDAI score, physical characteristics
(as measured by examination), concomitant medications taken and patient-reported outcomes including
the IBDQ. At weeks 0, 13, 49, 103 and 157 post randomisation, patients were also asked to provide
additional stool and blood samples for the central assessment of faecal calprotectin and TGN metabolite
levels, with endoscopic assessment at weeks 49 and 157 post randomisation.
Sample processing
Stool samples were collected at participating centres and frozen on site at –80 °C. Samples were then
shipped on dry ice in two batches during 2014 and 2015 to a central biochemistry laboratory at NHS Lothian
Western General Hospital in Edinburgh. Faecal calprotectin levels were all assessed using the CALPRO®
calprotectin enzyme-linked immunosorbent assay (alkaline phosphatase) (NovaTec Immundiagnostica GmbH,
Dietzenbach, Germany) and processed by technicians blinded to the treatment allocation. Blood samples for
TGN testing were sent ambient to Viapath (formerly GSTS Pathology; London, UK) for analysis in the Purine
Research Laboratory. An independent analyst blinded to the treatment allocation then assessed each level.
Therapeutic monitoring
All patients underwent regular safety blood monitoring every week for the initial 6 weeks and thereafter at
6-weekly intervals as long as the patient remained on the study drug. Blood samples were processed at
participating site laboratories. An independent central clinician who was blinded to the treatment allocation
reviewed results. Prespecified dose reduction or cessation then occurred in the event of abnormal monitoring
parameters. In the event of patient intolerance (profound nausea or persistent influenza-like symptoms),
protocol-driven dose reduction was also undertaken. If abnormal parameters improved after a temporary
stop, treatment was started again at a lower level. The central clinicians, blinded to the treatment allocation,
made all of these decisions.
To protect blinding, a programme of sham dose reductions was planned for patients on placebo. On the
advice of the DMC these were not undertaken, although the investigators were not informed of this
decision, hence protecting the study blinding.
Dose changes
All randomised patients allocated to the treatment group were given 1–1.5 mg/kg body weight, rounded
to the nearest 25 mg, to be taken as single daily dose in the morning. Treatment was on a maintenance
basis for 3 years or until the study drug was discontinued. Patients heterozygous for TPMT mutations were
prescribed MP at half the normal dose. The dose was adjusted up or down for weight changes according
to Table 1.
The blinded treatment of either MP or placebo could also be reduced or temporarily stopped following
patient intolerance (profound nausea or persistent influenza-like symptoms) or abnormal blood safety
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results. In these cases, the dose was reduced in accordance with Table 2 and not increased again during
the course of the trial. If symptoms or blood safety test result abnormalities persisted and were, in the view
of the investigator, of sufficient severity, the drug could be stopped. One of the blinded clinicians assessing
safety blood test results could also stop the drug.
Sample size
It was estimated that a study population of 182 evaluable patients would provide the trial with 80%
power to detect a reduction in the frequency of recurrence from 50% in the placebo group to 30% in the
treatment arm by 3 years at the 5% level of significance. Preliminary data from surgical and pathology
databases at the five Scottish recruiting sites indicated that this was an achievable target. In 2006–7,
approximately 130 ileocolonic resections were performed annually at the five Scottish recruiting sites
initially proposed. We estimated that 60% of the potential patients could be recruited, giving a sample
population of 234 patients and allowing for a 15% dropout rate. This would leave an evaluable
population of 200 patients over 3 years.
These figures were based on an intention-to-treat analysis, with the number needed to treat in order to
prevent one recurrence predicted to be five. It is notable that the treatment effect of 20% was lower than
in previously conducted studies (40% reduction in mild CD lesions and 75% reduction in more severe
lesions in Hanauer et al.;18 25% in Ardizzone et al.19). We also judged a treatment effect of 20% to be
appropriate because, given the side-effect profile of MP, it was arguable that a treatment effect of significantly
< 20% would be of limited clinical significance.
The sample size chosen had 80% power to detect a reduction in the frequency of recurrence from 50% in
the placebo group to 30% in the treatment arm by 3 years at the 5% level of significance.
TABLE 1 Dose of MP for patients with normal TPMT
Body weight (kg) Initial dose MP (mg)
Amount per body
weight (mg/kg)
< 33 50 alternate days 1–1.5
33–49.9 50 daily 1–1.5
50–74.9 50/100 alternate days 1–1.5
75–99.9 100 daily 1–1.33
100–150 150 daily 1–1.5
> 150 200 daily > 1
TABLE 2 Dose reduction schedule
Initial dose of MP (mg) Reduced dose of MP (mg) Per cent reduction
50 alternate days Stop 100
50 daily 50 alternate days 50
50/100 alternate days 50 daily 33
100 daily 50 daily 50
150 daily 50/100 alternate days 50
200 daily 100 daily 50
METHODS
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Interim analyses and stopping guidelines
An independent DMC reviewed trial data throughout the course of the trial, and there were no formal stopping
rules. The study recruitment period was extended and additional sites in England and Wales were opened
up to address concerns regarding the recruitment rate. Aside from this, the trial recruited according to plan.
Randomisation
Sequence generation
Randomisation was by a central, internet-based, secure password-protected randomisation database.
Patient identifiers and some clinical details were entered to confirm eligibility (inclusion and exclusion
criteria) and to prevent re-recruitment. The random allocation sequence was generated by the programmers
at a UK Clinical Research Collaboration-registered trials unit [Edinburgh Clinical Trials Unit (ECTU)].
Type of randomisation
Randomisation was stratified according to smoking status at baseline (yes/no) and by recruiting site
(31 blocks in total).
Implementation
Patients were individually enrolled by clinicians and research/specialist nurses at participating centres
(predominantly nursing staff) to one of the two parallel treatment groups. Randomisation had to be
within ≤ 3 months of surgery.
Once the randomisation procedure had been completed, a prescription was generated and provided to the
participant by a research nurse. The prescription contained details of the number of tablets and bottle
codes. The participant was asked to take the prescription to the site pharmacy to receive their allocated
blinded treatment. All subsequent prescriptions were generated and processed in the same way.
Blinding
Trial medication and packaging were identical in appearance. All study staff involved in the day-to-day
management of the trial, hospital staff and patients were blind to the study intervention. It was not possible
to tell which treatment a patient had been allocated from the study numbers, medication packets or
prescriptions. To further reduce the opportunity for accidental unblinding, the routine safety blood test
results were sent to a blinded central reader for assessment by an independent monitor at each participating
site who was not involved in the day-to-day management of the trial or the patient. The clinicians assessing
blood results and the study management team based in Edinburgh were blind to the assigned intervention.
Blinding was broken only for patients in whom an urgent clinical need was identified in terms of their clinical
management, typically following a CD relapse.
Trial data management
Trial data were manually entered into a web-based data collection system by researchers at participating
sites. In this system, active server pages supported web-based electronic case report forms and queried a
Microsoft SQL Server 2000 database (Microsoft Corporation, Redmond, WA, USA). Data were automatically
encrypted (using Secure Sockets Layer protocol V329) when entered into the forms, transferred via the
internet, decrypted and stored in a secure maintained network at the University of Edinburgh. The level of
encryption was dependent on the client’s web browser and operating system, but University of Edinburgh
servers could offer up to 256-bit encryption. In the same network, data were then queried using statistical
software (SAS; version 9.4, SAS Institute Inc., Cary, NC, USA) for the purposes of data analysis. All changes
to electronic data by site staff were traceable by date and user. A copy of the trial electronic case report
form is given in Report Supplementary Material 1.
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Statistical methods
An analysis was undertaken using SAS. The full statistical analysis plan is given in Report Supplementary
Material 2.
Primary outcomes
The primary outcome variable was postoperative recurrence of CD and its timing if it recurred. Analysis
was intention to treat and was based on the application of a Cox proportional hazards model. The primary
analysis included terms for treatment, the variables on which the randomisation was stratified (smoking
status and recruitment site) and adjusted for baseline values of previous treatment with MP and previous
treatment with azathioprine. Adjusted and unadjusted Cox proportional hazard ratios (HRs) are presented
as the comparison of MP versus placebo (reference), with a HR of < 1 indicating a treatment effect in
favour of MP. The adjusted analysis was considered to be the primary analysis of the primary outcome.
Secondary outcomes
The secondary outcome variable of clinical recurrence of CD (defined by a CDAI score of ≥ 150 points
together with a 100-point rise in the CDAI score from baseline) or the need for anti-inflammatory rescue
therapy or primary surgical intervention was analysed in the same manner as the primary outcome. For this
secondary outcome, as for the primary outcome, the adjusted analysis was considered the primary analysis.
Endoscopic recurrence using both the Rutgeerts and CDEIS scoring systems was summarised by time and
treatment group. Colonoscopy results at week 157 post randomisation (study visit 12) were compared
between the treatment groups using a chi-squared test to compare the incidence of positive colonoscopies
in the MP group and the placebo group. Both adjusted and unadjusted analyses were performed, with
the adjusted analysis incorporating the same covariates as for the primary outcome, with odds ratios
and 95% confidence intervals (CIs) presented. CDEIS scores at week 157 post randomisation were
compared between treatment groups using a t-test. Adjusted and unadjusted analyses were performed,
with treatment effects and 95% CIs presented. Faecal calprotectin results were summarised by time and
treatment group, both as a continuous measure and categorically.
The use of faecal calprotectin levels as a non-invasive marker of disease recurrence was examined in two
ways: first, it was considered as a time-dependent covariate in Cox proportional hazards model and,
second, levels were compared descriptively between those with negative and positive colonoscopies
(defined as negative if the Rutgeerts score was < i2 and positive if the Rutgeerts score was ≥ i2) at weeks
49 and 157 post randomisation. Similarly, TGN levels of the MP drug metabolite were also considered as a
time-dependent covariate in the Cox proportional hazards model.
The quality-of-life variables were analysed using repeated measures analysis of covariance to evaluate
treatment and treatment by time interactions. Quality of life, as measured by the IBDQ, was summarised at
each visit based on observed scores and change from baseline scores for each of the four IBDQ subscales
(bowel symptoms, emotional health, systemic systems and social function). Averages and totals across all
subscales were summarised similarly. In addition, the overall average and overall total scores were analysed
using a change from baseline repeated measures analysis of covariance to evaluate the effect of treatment
over time. Quality of life, as measured by the EuroQol-5 Dimensions (EQ-5D), was summarised by
treatment group across study visits.
METHODS
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Subgroup analyses
Subgroup analyses of the primary and secondary outcomes were carried out to assess for a treatment
effect in terms of thiopurine naivety, previous treatment with infliximab or methotrexate, previous surgery,
smoking status, duration of disease and age at diagnosis. The interaction between subgroup and treatment
was included in the Cox regression model to determine if the treatment effect differed by subgroup.
The same subgroups analysed for the primary and secondary outcomes were also analysed with respect to
colonoscopy results and CDEIS scores.
Publication policy
To safeguard the integrity of the trial, the primary results of the trial were published by the group as a
whole in collaboration with local investigators, and local investigators were acknowledged.30 The success
of the trial was dependent on the collaboration of many people and, particularly, the local investigators.
The results were, therefore, presented to the trial local investigators first.
Organisation
A TSC and a DMC were established. No formal charter was put in place, but both committees met formally
every 6 months throughout the trial in accordance with Medical Research Council (MRC)/Efficacy and
Mechanism Evaluation (EME) programme requirements following circulation of a standardised report.
Day-to-day management of the trial was overseen by a TMG comprising the chief investigator, the principal
investigator at the lead site in Edinburgh, the lead research nurse and the trial manager. Support from the
Chief Scientist Officer enabled a dedicated specialist nurse to support the trial at the initial five Scottish sites.
The local Comprehensive Local Research Networks supported research nursing time and employed or
re-allocated a research nurse to support all aspects of the trial at sites across England and Wales.
Confidentiality
Patients were identified by their trial number to ensure confidentiality. Stringent precautions were taken to
ensure confidentiality of names and addresses at ECTU and the sites. The chief investigator and local
investigators ensured conservation of records in areas to which access is restricted.
Audit
A risk-based monitoring strategy was implemented for all participating sites with onsite monitoring
conducted by either the sponsor’s monitoring team or a member of the TMG at a selected number of sites
depending on the issues identified at each site. Site visits were conducted during the course of the trial at
University College Hospital, London, on 5 December 2012, Torbay Hospital, Torquay, on 6 November
2013, Ninewells Hospital, Dundee, on 12 March 2014, Aberdeen Royal Infirmary, Aberdeen, on 11
September 2015, Bristol Royal Infirmary, Bristol, on 30 September 2015 and St Marks Hospital, Harrow, on
7 October 2015. A central audit of trial management was conducted on 12 December 2012 at the central
co-ordinating site at ECTU. In addition, an investigation was conducted by the sponsor following the
lodging of a formal complaint to the Medicines and Healthcare products Regulatory Agency in July 2013
regarding the wording on an information newsletter sent to a site regarding withdrawal procedures.
Recommendations were made following the investigation, but no evidence was found of improper
conduct regarding withdrawal procedures.
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Termination of the study
Before termination of recruitment, ECTU contacted all sites by telephone or e-mail in order to inform
sites of the final date for recruitment. Once the recruitment period had expired, the internet-based
randomisation database was disabled to prevent further recruitment. All recruited patients received trial
medication for a maximum of 3 years (36 months) post randomisation. The final patient’s final visit took place
in April 2015 and the database was locked in June 2015. A declaration of the end of trial form was sent to
the Multicentre Research Ethics Committee following the formal trial end date of 30 September 2015. The
following documents were archived in each site file to be kept for at least 20 years in accordance with MRC
policy: original consent forms, data forms, trial-related documents and correspondence. The trial master files at
ECTU will be archived for at least 20 years.
Funding
The costs for the study itself were covered by a grant from the MRC. See the MRC/EME programme
website for further project information.31 Additional support was provided by the Chief Scientist Officer.
Indemnity
If there was negligent harm during the clinical trial, then the NHS body owes a duty of care to the person
harmed and NHS indemnity covered NHS staff, medical academic staff with honorary contracts and those
conducting the trial. NHS indemnity did not offer no-fault compensation. The co-sponsors were responsible
for ensuring that proper provision was made for insurance or indemnity to cover their liability and the
liability of the chief investigator and staff.
Ethics approval and research governance
Ethics approval for the study was given by Scotland A Research Ethics Committee in August 2007 (reference
number 07/MRE00/74). Local NHS management approval and appropriate site-specific assessments were
obtained at each participating NHS trust. The trial was registered with the International Standard Randomised
Controlled Trial Register under the reference number ISRCTN89489788 along with the European Clinical
Trials Database under the reference number 2006-005800-15, and the UK Clinical Research Network
Portfolio Database under the reference number 5813. A summary of the changes made to the original
protocol is given in Report Supplementary Material 3 and an overview of all participant information and
consent forms is given in Report Supplementary Material 4.
METHODS
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Chapter 3 Results
Recruitment
Patients were recruited from the following dates: June 2008 to April 2012 (46 months). The addition of
24 sites in England and Wales was in response to slower than anticipated recruitment over the initial
24 months. Initial study recruitment projection figures were based on surgical data collected from the five
original Scottish hospitals in the 5 years prior to the grant application. These data indicated that 60% of
patients would proceed from surgery into the trial. In practice, the proportion of patients recruited into the
trial following surgery at the initial five sites was 30% as a result of higher than expected contraindications
to the trial entry and patients’ greater than anticipated reluctance to receive placebo. An extension to the
study recruitment period was granted in 2010, along with approval for the trial to be extended to additional
centres across England and Wales. The trial completed recruitment on target according to the revised
schedule on 23 April 2012, with the final patient’s final visit completed on schedule in April 2015.
Participant flow
A Consolidated Standards of Reporting Trials (CONSORT) diagram for recruitment is provided in Figure 1.
In total, 328 patients were screened and 240 were randomised, thereby meeting and slightly exceeding
the recruitment target of 234. Seventy-eight per cent of eligible patients were randomised to the study
following screening, with 22% of patients declining to take part.
Screened
(n = 328)
Ineligible or declined 
(n = 88)
Randomised
(n = 240)
Randomly allocated
to MP
(n = 128)
Primary analysis
(n = 128)
Allocation
Enrolment
Randomly allocated
to placebo
(n = 112)
Analysis
Primary analysis
(n = 112)
Continued on drug 
to visit 12
(n = 62)
• Withdrawn, n = 8
• Lost to follow-up, 
   n = 7
• Deceased, n = 0
• Adverse event, n = 39
• Safety blood test, 
   n = 12
Continued on drug 
to visit 12
(n = 42)
• Withdrawn, n = 13
• Lost to follow-up, 
   n = 9
• Deceased, n = 1
• Adverse event, n = 41
• Safety blood test, 
   n = 6
Treatment
period
Primary end point,
n = 16
Secondary end 
point, n = 34
Primary end point,
n = 26
Secondary end 
point, n = 40
FIGURE 1 The CONSORT diagram for TOPPIC.
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All 240 randomised patients were analysed. A total of 128 (53%) participants were randomised to receive
MP and 112 (47%) to placebo. All randomised patients received at least one dose of study drug. A
protocol violation was recorded involving a participant who was prescribed a study drug from the wrong
treatment arm 6 weeks post randomisation; the error was reported and the correct study drug issued.
Summary of ineligible and non-recruited patients
Table 3 summarises the number of ineligible and non-recruited patients at the participating centres.
Five centres did not randomise any patients during the recruitment period and were closed early.
TABLE 3 Ineligible and non-recruited patients across participating centres
Centre
number Centre name
Pre-screening
ineligibles
Number of
candidates
Number
randomised
Number of
ineligibles
Number of
non-recruits
11 Edinburgh 150 91 78a 1 14
12 Aberdeen 62 23 17 1 4
13 Dundee 49 29 21 2 6
14 Glasgow Stobhill 15 25 19 3 3
15 Glasgow Royal
Infirmary
29 15 8 1 6
16 Exeter 25 28 11 0 17
17 Coventry 15 6 6 0 0
18 Liverpool 25 14 8 2 3
19 Manchester 20 5 3 0 2
20 Bristol 3 6 5 0 1
21 UCLH 59 7 5 0 2
24 Oxford 32 12 9 2 1
25 Salford 31 4 2 1 1
26 Swansea 11 6 4 1 1
27 Royal Free 14 2 2 0 0
28 Barts 24 1 1 0 0
29 Torbay 11 6 6 0 0
30 Norfolk & Norwich 0 1 0 0 1
31 Stockton 4 1 0 0 1
32 Southampton 18 4 2 1 1
33 Plymouth 20 3 3 0 0
34 Durham 34 8 6b 1 2
35 Hull 22 3 3 0 0
36 Leeds 36 10 8 1 1
38 Wolverhampton 36 0 0 0 0
39 North Staffordshire 0 2 1 0 1
40 Nottingham 15 2 2 0 0
RESULTS
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Characteristics used for stratification of randomisation
Randomised patients were stratified according to centre and smoking status (31 blocks in total). Table 4
shows the numbers of patients randomised per recruiting centre, with the Edinburgh site recruiting the
highest proportion of patients (32.5%). Smoking status (defined as those patients smoking more than one
cigarette per day) is shown in Table 5.
Characteristics at pre-assessment
Characteristics of randomised patients at pre-assessment are shown in Table 6. The group randomised
to MP had slightly more patients who had previously been treated with MP, azathioprine and
immunosuppressant agents, although all other demographics and characteristics were similar.
Patient characteristics at randomisation
Table 7 shows the baseline characteristics of participants at randomisation (week 0). The two treatment
groups were similar across the variables assessed, which included weight, faecal calprotectin levels, and
CDAI or IBDQ scores.
Adherence to trial protocol
Adherence to trial medication
A summary of the duration of trial medication is shown in Table 8, with Figure 2 showing a Kaplan–Meier
plot of the duration of medication in years. The reasons for non-completion of the full treatment period
are detailed in Table 9. One hundred and thirty-six patients (56.7%) did not complete 3 years of trial
medication, with 80 (58.8%) patients not completing as the result of adverse events, 21 (15.4%) because
of early withdrawal, 18 (13.2%) because of abnormal safety blood results, 16 (11.8%) being lost to
follow-up and one (0.7%) patient dying.
TABLE 3 Ineligible and non-recruited patients across participating centres (continued )
Centre
number Centre name
Pre-screening
ineligibles
Number of
candidates
Number
randomised
Number of
ineligibles
Number of
non-recruits
42 St Marks 14 1 1 0 0
43 Rotherham 20 5 4 0 0
44 Birmingham Queen
Elizabeth
0 3 2 1 0
45 Inverness 2 1 1 0 0
46 Darlington 14 4 2 2 0
47 Bradford 5 1 0 0 1
48 Birmingham City 11 0 0 0 0
UCLH, University College London Hospital.
a Two participants at Edinburgh transferred from other sites (Aberdeen and Liverpool).
b One participant at Rotherham transferred from another site (Durham).
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TABLE 4 Number of patients randomised at each recruiting centre
Centre name
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
Edinburgh 38 (29.7) 40 (35.7) 78 (32.5)
Aberdeen 9 (7.0) 8 (7.1) 17 (7.1)
Dundee 11 (8.6) 10 (8.9) 21 (8.8)
Glasgow Stobhill 10 (7.8) 9 (8.0) 19 (7.9)
Glasgow Royal Infirmary 5 (3.9) 3 (2.7) 8 (3.3)
Exeter 6 (4.7) 5 (4.5) 11 (4.6)
Coventry 3 (2.3) 3 (2.7) 6 (2.5)
Liverpool 6 (4.7) 2 (1.8) 8 (3.3)
Manchester 2 (1.6) 1 (0.9) 3 (1.3)
Bristol 2 (1.6) 3 (2.7) 5 (2.1)
UCLH 3 (2.3) 2 (1.8) 5 (2.1)
Oxford 5 (3.9) 4 (3.6) 9 (3.8)
Salford 2 (1.6) 0 (0.0) 2 (0.8)
Swansea 3 (2.3) 1 (0.9) 4 (1.7)
Royal Free 1 (0.8) 1 (0.9) 2 (0.8)
Barts 1 (0.8) 0 (0.0) 1 (0.4)
Torbay 4 (3.1) 2 (1.8) 6 (2.5)
Southampton 1 (0.8) 1 (0.9) 2 (0.8)
Plymouth 2 (1.6) 1 (0.9) 3 (1.3)
Durham 3 (2.3) 3 (2.7) 6 (2.5)
Hull 1 (0.8) 2 (1.8) 3 (1.3)
Leeds 4 (3.1) 4 (3.6) 8 (3.3)
North Staffordshire 1 (0.8) 4 (3.6) 8 (3.3)
Nottingham 1 (0.8) 1 (0.9) 2 (0.8)
St Marks 0 (0.0) 1 (0.9) 2 (0.8)
Rotherham 2 (1.6) 2 (1.8) 4 (1.7)
Birmingham Queen Elizabeth 0 (0.0) 2 (1.8) 2 (0.8)
Inverness 1 (0.8) 0 (0.0) 1 (0.4)
Darlington 1 (0.8) 1 (0.9) 2 (0.8)
UCLH, University College London Hospital.
TABLE 5 Smoking status of randomised patients
Smoking status
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
Smoker 29 (22.7) 26 (23.2) 55 (22.9)
Non-smoker 99 (77.3) 86 (76.8) 185 (77.1)
RESULTS
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TABLE 6 Patient characteristics at pre-assessment
Patient characteristic
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
Sex
Female 79 (61.7) 67 (59.8) 146 (60.8)
Male 49 (38.3) 45 (40.2) 94 (39.2)
Previous treatment with MP
Yes 14 (10.9) 5 (4.5) 19 (7.9)
No 114 (89.1) 106 (94.6) 220 (91.7)
Missing 0 (0.0) 1 (0.9) 1 (0.4)
Previous treatment with azathioprine
Yes 80 (62.5) 47 (42.0) 127 (52.9)
No 48 (37.5) 64 (57.1) 112 (46.7)
Missing 0 (0.0) 1 (0.9) 1 (0.4)
Previous treatment with infliximab
Yes 21 (16.4) 15 (13.4) 36 (15.0)
No 104 (81.3) 96 (85.7) 200 (83.3)
Missing 3 (2.3) 1 (0.9) 4 (1.7)
Previous treatment with methotrexate
Yes 8 (6.3) 7 (6.3) 15 (6.3)
No 120 (93.8) 104 (92.9) 224 (93.3)
Missing 0 (0.0) 1 (0.9) 1 (0.4)
Previous treatment with other corticosteroids
Yes 97 (75.8) 79 (70.5) 176 (73.3)
No 31 (24.2) 32 (28.6) 63 (26.3)
Missing 0 (0.0) 1 (0.9) 1 (0.4)
Any previous immunosuppressants
Yes 112 (87.5) 86 (76.8) 198 (82.5)
No 16 (12.5) 25 (22.3) 41 (17.1)
Missing 0 (0.0) 1 (0.9) 1 (0.4)
CD location
Ileal 54 (42.2) 39 (34.8) 93 (38.8)
Colonic 4 (3.1) 2 (1.8) 6 (2.5)
Ileocolonic 70 (54.7) 70 (62.5) 140 (58.3)
Missing 0 (0.0) 1 (0.9) 1 (0.4)
continued
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TABLE 6 Patient characteristics at pre-assessment (continued )
Patient characteristic
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
CD type
Non-stricturing non-penetrating 50 (39.1) 45 (40.2) 95 (39.6)
Stricturing 63 (49.2) 46 (41.1) 109 (45.4)
Penetrating 15 (11.7) 19 (17.0) 34 (14.2)
Missing 0 (0.0) 2 (1.8) 2 (0.8)
Previous surgery
Yes 46 (35.9) 28 (25.0) 74 (30.8)
No 82 (64.1) 83 (74.1) 165 (68.8)
Missing 0 (0.0) 1 (0.9) 1 (0.4)
TPMT
Normal 116 (90.6) 96 (85.7) 212 (88.3)
Heterozygous 12 (9.4) 16 (14.3) 28 (11.7)
Age at diagnosis (years)
≤ 40 103 (80.5) 87 (77.7) 190 (79.2)
> 40 25 (19.5) 23 (20.5) 48 (20.0)
Unknown 0 (0.0) 2 (1.8) 2 (0.8)
Duration of CD (years)
≤ 1 37 (28.9) 41 (36.6) 78 (32.5)
> 1 91 (71.1) 69 (61.6) 160 (66.7)
Unknown 0 (0.0) 2 (1.8) 2 (0.8)
Age (years)
Mean 39.2 38.2 38.7
Median 38.0 36.0 38.0
SD 12.8 13.4 13.1
Q1, Q3 28, 50 28, 48 28, 48
Min., max. 17, 67 17, 75 17, 75
n (missing) 128 (0) 112 (0) 240 (0)
Duration of CD (years)
Mean 7.7 7.6 7.6
Median 3.0 4.0 3.0
SD 9.7 9.5 9.6
Q1, Q3 0,11 0, 11 0,11
Min., max. 0, 39 0, 47 0,47
n (missing) 128 (0) 110 (2) 238 (2)
max., maximum; min., minimum; Q1, quartile 1; Q3, quartile 3; SD, standard deviation.
RESULTS
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TABLE 7 Patient characteristics at randomisation
Patient characteristic
Treatment
Overall (N= 240)MP (N= 128) Placebo (N= 112)
Weight (kg)
Mean 70.7 70.7 70.7
Median 69.9 68.8 69.4
SD 14.4 13.7 14.0
Q1, Q3 58.5, 80.1 62.0, 76.8 60.0, 78.1
Min., max. 44.3, 111.9 43.6, 123.8 43.6, 123.8
n (missing) 128 (0) 112 (0) 240 (0)
Height (cm)
Mean 168 169 169
Median 168 168 168
SD 9 9 9
Q1, Q3 161, 175 162, 177 161, 176
Min., max. 149, 193 150, 193 149, 193
n (missing) 128 (0) 112 (0) 240 (0)
Faecal calprotectin (µg/g of faeces)
Mean 124.4 160.1 141.2
Median 80.0 77.5 80.0
SD 170.9 213.9 192.7
Q1, Q3 30, 125 40, 165 40, 140
Min., max. 0, 920 0, 1040 0, 1040
n (missing) 108 (20) 96 (16) 204 (36)
Neutrophil count (109/l)
Mean 4.45 4.22 4.34
Median 4.20 3.88 4.10
SD 1.76 1.63 1.70
Q1, Q3 3.4, 5.2 3.0, 5.0 3.2, 5.1
Min., max. 1.5, 13.8 1.7, 8.9 1.5, 13.8
n (missing) 127 (1) 111 (1) 238 (2)
CDAI score
Mean 130 121 125
Median 111 112 112
SD 86 72 80
Q1, Q3 63, 179 63, 161 63, 169
Min., max. 2, 459 5, 368 2, 459
n (missing) 128 (0) 112 (0) 240 (0)
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TABLE 7 Patient characteristics at randomisation (continued )
Patient characteristic
Treatment
Overall (N= 240)MP (N= 128) Placebo (N= 112)
IBDQ: overall average
Mean 5.19 5.31 5.24
Median 5.38 5.56 5.47
SD 0.99 0.94 0.97
Q1, Q3 4.4, 5.9 4.9, 6.0 4.7, 6.0
Min., max. 1.9, 7.0 2.7, 6.7 1.9, 7.0
n (missing) 128 (0) 111 (1) 239 (1)
IBDQ: overall total
Mean 166 170 168
Median 172 178 175
SD 32 30 31
Q1, Q3 142, 188 156, 191 150, 191
Min., max. 61, 223 85, 215 61, 223
n (missing) 128 (0) 111 (1) 239 (1)
SF-36: physical component score
Mean 44.2 42.6 43.5
Median 45.0 43.2 44.5
SD 9.4 10.5 9.9
Q1, Q3 37, 52 36, 51 36, 52
Min., max. 22, 60 6, 60 6, 60
n (missing) 124 (4) 110 (2) 234 (6)
SF-36: mental component score
Mean 45.3 46.4 45.8
Median 47.0 49.7 47.7
SD 11.9 12.5 12.3
Q1, Q3 38, 55 39, 56 38, 56
Min., max. 13, 66 15, 69 13, 69
n (missing) 124 (4) 110 (2) 234 (6)
EQ-5D: mobility, n (%)
I have no problems in walking about 107 (83.6) 87 (77.7) 194 (80.8)
I have some problems in walking about 21 (16.4) 24 (21.4) 45 (18.8)
I am confined to bed 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 1 (0.9) 1 (0.4)
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TABLE 7 Patient characteristics at randomisation (continued )
Patient characteristic
Treatment
Overall (N= 240)MP (N= 128) Placebo (N= 112)
EQ-5D: self-care, n (%)
I have no problems with self-care 125 (97.7) 104 (92.9) 229 (95.4)
I have some problems washing or dressing myself 3 (2.3) 7 (6.3) 10 (4.2)
I am unable to wash or dress myself 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 1 (0.9) 1 (0.4)
EQ-5D: usual activities, n (%)
I have no problems 75 (58.6) 61 (54.4) 136 (56.7)
I have some problems 47 (36.7) 41 (36.6) 88 (36.7)
I am unable to perform my usual activities 6 (4.7) 9 (8.0) 15 (6.3)
Missing 0 (0.0) 1 (0.9) 1 (0.4)
EQ-5D: pain/discomfort, n (%)
I have no pain or discomfort 64 (50.0) 56 (50.0) 120 (50.0)
I have moderate pain or discomfort 61 (47.7) 54 (48.2) 115 (47.9)
I have extreme pain or discomfort 3 (2.3) 1 (0.9) 4 (1.7)
Missing 0 (0.0) 1 (0.9) 1 (0.4)
EQ-5D: anxiety/depression, n (%)
I am not anxious or depressed 93 (72.7) 74 (66.1) 167 (69.6)
I am moderately anxious or depressed 33 (25.8) 34 (30.4) 67 (27.9)
I am extremely anxious or depressed 2 (1.6) 3 (2.7) 5 (2.1)
Missing 0 (0.0) 1 (0.9) 1 (0.4)
max., maximum; min., minimum; Q1, quartile 1; Q3, quartile 3; SD, standard deviation; SF-36, 36-Item Short Form
Health Survey.
TABLE 8 Duration of trial medication
Duration of trial medication
(years)
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
≥ 3 62 (48.4) 42 (37.5) 104 (43.3)
< 3 66 (51.6) 70 (62.5) 136 (56.7)
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Dosage was adjusted throughout the trial in accordance with the protocol (see Tables 1 and 2). Table 10
provides a summary of doses at first and final visits. Table 11 summarises doses at final visit compared with
dose first allocated. Only a small proportion of patients continued on the same dosage (n = 63, 26.3%) or at
an increased dosage (n = 13, 5.4%); in the majority either the dose was decreased (n = 68, 28.3%) or the
trial medication was stopped altogether (n = 96, 40.0%). The dosage was decreased in a higher proportion
of patients in the MP group (39.1%) than in the placebo group (16.1%), whereas a higher proportion in
the placebo group than in the MP group remained on the same dosage (37.5% compared with 16.4%,
respectively) or stopped trial medication (42.9% compared with 37.5, respectively). The dose was increased
in a small number of patients, but the proportion was marginally higher in the MP group than in the placebo
group (7.0% compared with 3.6%).
Adherence to the trial visits and withdrawal
Table 12 shows the number of patients who reached the end of the study (week 157 post randomisation;
n= 161, 67.1%). Seventy-nine patients did not reach the final study visit, with 52 withdrawn early at their own
choice or by their clinician and a further 26 being lost to follow-up or non-attenders; there was one death.
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FIGURE 2 Kaplan–Meier plot showing duration of trial medication in years.
TABLE 9 Reasons for randomised patients not completing 3 years of trial medication
Reason
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
Adverse event 39 (59.1) 41 (58.6) 80 (58.8)
Blood test result 12 (18.2) 6 (8.6) 18 (13.2)
Early withdrawal 8 (12.1) 13 (18.6) 21 (15.4)
Deceased 0 (0.0) 1 (1.4) 1 (0.7)
Lost to follow-up 7 (10.6) 9 (12.9) 16 (11.8)
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TABLE 10 Summary of doses at first and final visit
Dosage
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
Dose (mg) allocated at first visit
50 alternate days 0 (0.0) 1 (0.9) 1 (0.4)
50 daily 17 (13.3) 17 (15.2) 34 (14.2)
50/100 alternate days 73 (57.0) 62 (55.4) 135 (56.3)
100 daily 34 (26.6) 27 (24.1) 61 (25.4)
150 daily 4 (3.1) 5 (4.5) 9 (3.8)
Dose allocated at final visit
Stop 48 (37.5) 48 (42.9) 96 (40.0)
50 alternate days 17 (13.3) 5 (4.5) 22 (9.2)
50 daily 33 (25.8) 20 (17.9) 53 (22.1)
50/100 alternate days 17 (13.3) 25 (22.3) 42 (17.5)
100 daily 13 (10.2) 13 (11.6) 26 (10.8)
150 daily 0 (0.0) 1 (0.9) 1 (0.4)
TABLE 11 Summary of doses at final visit, compared with dose first allocated
Final dose change
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
Dose decreased 50 (39.1) 18 (16.1) 68 (28.3)
Dose stayed the same 21 (16.4) 42 (37.5) 63 (26.3)
Dose increased 9 (7.0) 4 (3.6) 13 (5.4)
Trial medication stopped 48 (37.5) 48 (42.9) 96 (40.0)
TABLE 12 Summary of withdrawal at final study visit (week 157 post randomisation)
Parameter Category
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
Week 12
(week 157, n= 161)
Patient attended 89 (69.5) 72 (64.3) 161 (67.1)
Patient did not attend 7 (5.5) 2 (1.8) 9 (3.8)
Early withdrawal 24 (18.8) 26 (23.2) 50 (20.8)
Withdrawn by clinician 1 (0.8) 1 (0.9) 2 (0.8)
Lost to follow-up 7 (5.5) 10 (8.9) 17 (7.1)
Deceased 0 (0.0) 1 (0.9) 1 (0.4)
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The length of patient follow-up, in months, is shown in Table 13. The mean follow-up period was
28.6 months overall (maximum follow-up was 48 months), with a slightly longer follow-up in the MP group
than in the placebo group (29.3 months vs. 27.8 months).
Adherence to study blinding
Treatment blinding was broken for 12 patients, and the reasons are listed in Table 14.
TABLE 13 Length of patient follow-up
Months
Treatment
Overall (N= 240)MP (N= 128) Placebo (N= 112)
Mean 29.3 27.8 28.6
Median 36.0 36.0 36.0
SD 12.2 12.2 12.2
Q1, Q3 28, 36 20, 36 23, 36
Min., max. 0, 48 0, 38 0, 48
n (missing) 128 (0) 112 (0) 240 (0)
max., maximum; min., minimum; Q1, quartile 1; Q3, quartile 3; SD, standard deviation.
TABLE 14 Emergency unblinding by treatment allocation with reasons
Patient ID Centre
Date
ExplanationRandomisation Unblinding
Treatment group
MP
11003 Edinburgh 13 June 2008 27 January 2009 Primary end point reached
11030 Edinburgh 3 November 2009 27 February 2014 Adverse event post trial
11064 Edinburgh 21 February 2011 5 April 2012 Other
Placebo
11053 Edinburgh 18 August 2010 29 February 2012 Other
11078 Edinburgh 5 September 2011 31 May 2012 Other
11082 Edinburgh 13 September 2011 2 September 2013 Other
12002 Aberdeen 30 October 2008 3 February 2009 SUSAR
12014 Aberdeen 31 March 2010 17 May 2010 SUSAR
14010 Glasgow Stobhill 6 October 2009 26 October 2009 SUSAR
16004 Exeter 17 June 2010 25 November 2010 SUSAR
18007 Liverpool 3 May 2011 9 July 2013 SUSAR
44003 Birmingham Queen Elizabeth 16 January 2012 17 March 2015 Adverse event post trial
ID, identification; SUSAR, suspected unexpected serious adverse reaction.
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Adherence to trial procedures
A total of nine protocol violations were recorded during the course of the study: five relating to study
sample storage and four relating to study dosage and affecting specific sites and specific patients. A total
of 216 deviations were recorded. The deviation categories are provided in Table 15.
Concomitant medication
Concomitant medications are shown in Table 16.
Outcomes and estimation
Primary outcome
The primary outcome was postoperative clinical recurrence of CD, defined as a CDAI score of > 150 points
with an increase from baseline of 100 points, together with the need for anti-inflammatory rescue therapy
or primary surgical intervention.
As shown in Tables 17 and 18, the primary outcome was reached by 42 patients (17.5%); 16 out of 128
(12.5%) on MP versus 26 out of 112 (23.2%) on placebo (HR 0.535, 95% CI 0.27 to 1.06; adjusted
p = 0.073; HR 0.527, 95% CI 0.28 to 0.99; unadjusted p = 0.046). Of the 42 who reached the primary
end point, 37 participants (88%) met the CDAI score trigger and had rescue therapy initiated, whereas five
(12%) met the CDAI score trigger and had both rescue therapy and primary surgical intervention.
The HR of < 1 for both the adjusted and unadjusted analyses indicates a treatment effect in favour of MP.
The associated confidence limits for the adjusted and unadjusted results demonstrate borderline statistical
significance at the 5% level.
For the 42 patients who reached primary outcome, Table 19 shows the follow-up and recurrence for the
26 (10.8%) participants reaching the primary outcome and completing the full 36-month follow-up, and
for the 16 (6.7%) participants reaching the primary outcome with < 36 months of follow-up in the trial.
Secondary outcome: clinical recurrence
The secondary outcome of clinical recurrence was postoperative clinical recurrence of CD, defined as a CDAI
score of > 150 points with an increase from baseline of 100 points, or the need for anti-inflammatory rescue
therapy or primary surgical intervention.
TABLE 15 Protocol deviations by category
Protocol deviation Overall (n)
Study visit missed or out of window 49
Safety bloods missed or out of window 89
Colonoscopy missed or out of window 22
Questionnaire missed or out of window 3
Calprotectin sample missed or out of window 25
Medication miscounted or taken incorrectly 11
TGN sample missed or out of window 3
Other 14
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TABLE 16 Summary of concomitant medication
Parameter
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
Concomitant medications taken?
Yes 119 (93.0) 111 (99.1) 230 (95.8)
No 9 (7.0) 1 (0.9) 10 (4.2)
Total number of concomitant medications 1051 965 2016
Number of prohibited and non-prohibited medications
Prohibited 93 (8.8) 126 (13.1) 219 (10.9)
Non-prohibited 958 (91.2) 839 (86.9) 1797 (89.1)
Number of occasions concomitant medications taken
1 7 (5.9) 7 (6.3) 14 (6.1)
2 10 (8.4) 12 (10.8) 22 (9.6)
3 9 (7.6) 7 (6.3) 16 (7.0)
4 9 (7.6) 5 (4.5) 14 (6.1)
5 12 (10.1) 12 (10.8) 24 (10.4)
6–10 31 (26.1) 33 (29.7) 64 (27.8)
11–15 22 (18.5) 21 (18.9) 43 (18.7)
> 15 19 (16.0) 14 (12.6) 33 (14.3)
Requiring rescue therapy for CD?
Yes 30 (25.2) 37 (33.3) 67 (29.1)
No 89 (74.8) 74 (66.7) 163 (70.9)
Number of occasions rescue therapy taken for CD
1 10 (33.3) 10 (27.0) 20 (29.9)
2 3 (10.0) 11 (29.7) 14 (20.9)
3 8 (26.7) 6 (16.2) 14 (20.9)
4 4 (13.3) 4 (10.8) 8 (11.9)
5 1 (3.3) 2 (5.4) 3 (4.5)
> 5 4 (13.3) 4 (10.8) 8 (11.9)
TABLE 17 Summary of primary outcome
Primary outcome
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
Primary outcome met?
Yes 16 (12.5) 26 (23.2) 42 (17.5)
No 112 (87.5) 86 (76.8) 198 (82.5)
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The secondary outcome events and statistical analysis are summarised in Tables 20 and 21 respectively.
The secondary outcome was reached by 74 (30.8%) patients: 34 out of 128 (26.6%) on MP versus 40 out
of 112 (35.7%) on placebo (HR 0.737, 95% CI 0.44 to 1.23; adjusted p = 0.243; HR 0.746, 95% CI 0.47
to 1.18; unadjusted p = 0.211). Similar to the primary outcome, the HRs are in favour of MP, but the
associated CIs indicate a lack of statistical significance.
Crohn’s Disease Activity Index score
The mean score change from baseline in the CDAI for patients is shown in Figure 3 from randomisation at
visit 2 (week 0) to the final study visit at visit 12 (104 weeks post randomisation).
Secondary outcome: surgical intervention
Tables 22 and 23 present a summary of the patients who have had surgical intervention and the associated
time (in days) to the intervention.
TABLE 18 Primary outcome statistical analysis (Cox proportional hazards model)
Analysis type HR
95% CI level
p> χ2Lower Upper
Adjusted 0.535 0.27 1.06 0.073
Unadjusted 0.527 0.28 0.99 0.046
TABLE 19 Follow-up and recurrence
Follow-up and recurrence
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
Follow-up of ≥ 3 years and primary outcome 11 (8.6) 15 (13.4) 26 (10.8)
Follow-up of < 3 years and primary outcome 5 (3.9) 11 (9.8) 16 (6.7)
Other 112 (87.5) 86 (76.8) 198 (82.5)
TABLE 20 Summary of secondary outcome events
Secondary outcome
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
Secondary outcome met?
Yes 34 (26.6) 40 (35.7) 74 (30.8)
No 94 (73.4) 72 (64.3) 166 (69.2)
TABLE 21 Secondary statistical analysis (Cox proportional hazards model)
Analysis type HR
95% CI limit
p> χ2Lower Upper
Adjusted 0.737 0.44 1.23 0.243
Unadjusted 0.746 0.47 1.18 0.211
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FIGURE 3 Mean change from baseline in CDAI scores per study visit.
TABLE 22 Surgical interventions: time to surgical intervention
Days
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
Had surgical intervention?
Yes 3 (2.3) 4 (3.6) 7 (2.9)
No 125 (97.7) 108 (96.4) 233 (97.1)
Number of occasions that surgery was undertaken
1 2 (66.7) 4 (100) 6 (85.7)
2 1 (33.3) 0 (0.0) 1 (14.3)
TABLE 23 Surgical interventions: time (days) to surgical intervention
Time to surgical intervention (days)
Treatment
Overall (N= 240)MP (N= 128) Placebo (N= 112)
Mean 460.7 582.8 530.4
Median 629.0 581.0 629.0
SD 357.6 511.7 421.7
Q1, Q3 50, 703 149, 1017 60, 924
Min., max. 50, 703 60, 1109 50, 1109
n (missing) 3 (0) 4 (0) 7 (0)
max., maximum; min., minimum; Q1, quartile 1; Q3, quartile 3; SD, standard deviation.
i2: ≥ 5 aphthous lesions with normal mucosa between lesions, or skip areas of larger lesions or lesions confined to the
ileocolonic anastomosis.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
28
A small number of patients (7, 2.9%) had a secondary surgical intervention during the course of the trial,
with similar numbers across the MP and placebo groups. The mean time to surgical intervention was
530.4 days, with a mean time being shorter in the MP group than in the placebo group (460.7 days vs.
582.8 days).
Secondary outcome: endoscopic recurrence
Tables 24 and 25 present a summary of endoscopic recurrence, as defined by Rutgeerts score, at visits 6
(week 49) and 12 (week 157), categorised by overall score and as either negative or positive. Figure 4
presents the number of negative and positive scores as bar charts.
Colonoscopy results (defined as negative or positive using the Rutgeerts score) are also summarised and
the results of the statistical analysis of visit 12 colonoscopy results are presented in Table 26.
Comparing the incidence of positive colonoscopies at visit 12 for the MP group with the placebo group
gave an adjusted odds ratio of 0.66 (95% CI 0.26 to 1.67; p = 0.382) and an unadjusted odds ratio of
0.79 (95% CI 0.39 to 1.61; p = 0.516), indicating no significant difference between treatment arms.
Endoscopic recurrence was also assessed using CDEIS score. Figure 5 shows CDEIS scores in a box plot,
with a higher CDEIS score indicating greater severity of disease. The results of the statistical analysis are
shown in Table 27, with an adjusted treatment effect of –0.612 (95% CI –1.92 to 0.69; p = 0.354), where
an effect < 0 indicates a treatment effect in favour of MP. Higher CDEIS scores were recorded for the
placebo group than for those patients allocated to MP at visits 6 and 12, although the difference was not
statistically significant.
TABLE 24 Summary of colonoscopy results defined by Rutgeerts score and categorised by score
Time point
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
Visit 6 (week 49, n= 208)
i0: no lesions 33 (29.7) 14 (14.4) 47 (22.6)
i1: ≤ 5 aphthous ulcers 24 (21.6) 28 (28.9) 52 (25.0)
i2: > 5 aphthous ulcers 18 (16.2) 19 (19.6) 37 (17.8)
i3: diffuse aphthous ileitis 11 (9.9) 13 (13.4) 24 (11.5)
i4: diffuse ileal inflammation 5 (4.5) 3 (3.1) 8 (3.8)
Other 4 (3.6) 0 (0.0) 4 (1.9)
Missing 16 (14.4) 20 (20.6) 36 (17.3)
Visit 12 (week 157, n= 161)
i0: no lesions 20 (22.5) 9 (12.5) 29 (18.0)
i1: ≤ 5 aphthous ulcers 18 (20.2) 20 (27.8) 38 (23.6)
i2: > 5 aphthous ulcers 18 (20.2) 11 (15.3) 29 (18.0)
i3: diffuse aphthous ileitis 4 (4.5) 5 (6.9) 9 (5.6)
i4: diffuse ileal inflammation 7 (7.9) 12 (16.7) 19 (11.8)
Other 2 (2.2) 2 (2.8) 4 (2.5)
Missing 20 (22.5) 13 (18.1) 33 (20.5)
Visit 6 was week 49 post randomisation and visit 12 was week 157 post randomisation.
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FIGURE 4 Colonoscopy by study visit (visit 6 was week 49 post randomisation and visit 12 was week 157 post
randomisation). (a) Visit 6 and (b) visit 12.
TABLE 26 Visit 12 colonoscopy analysis results
Analysis type Visit 12 odds ratio
95% CI limit
p-valueLower Upper
Adjusted 0.66 0.26 1.67 0.382
Unadjusted 0.79 0.39 1.61 0.516
TABLE 25 Summary of colonoscopy results defined by Rutgeerts score as either negative or positive
Time point
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
Visit 6 (week 49, n= 208)
Negative (< i2) 57 (51.4) 42 (43.3) 99 (47.6)
Positive (≥ i2) 34 (30.6) 35 (36.1) 69 (33.2)
Other 4 (3.6) 0 (0.0) 4 (1.9)
Missing 16 (14.4) 20 (20.6) 36 (17.3)
Visit 12 (week 157, n= 161)
Negative (< i2) 38 (42.7) 29 (40.3) 67 (41.6)
Positive (≥ i2) 29 (32.6) 28 (38.9) 57 (35.4)
Other 2 (2.2) 2 (2.8) 4 (2.5)
Missing 20 (22.5) 13 (18.1) 33 (20.5)
Visit 6 was week 49 post randomisation and visit 12 was week 157 post randomisation.
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Secondary outcome: faecal calprotectin levels
Faecal calprotectin results were summarised by time and treatment group both as a continuous measure
and categorically. The continuous change from baseline to each time point was also summarised and is
presented in Figure 6, indicating an increase from baseline across all visits in the placebo group, in contrast
to a decrease from baseline across all visits in the MP group. Figure 7 shows a categorical summary of
faecal calprotectin levels, indicating the proportions in both MP and placebo groups.
Faecal calprotectin levels were also assessed as a non-invasive marker of clinical recurrence of CD by
incorporating it as a time-varying covariate in the Cox proportional hazards model. Tables 28 and 29
summarise faecal calprotectin levels by colonoscopy result at visits 6 and 12. The results of the statistical
analysis are presented in Table 30 and indicate that faecal calprotectin levels are a significant predictor of
the primary outcome. For each 100 µg/g increase in faecal calprotectin, the probability of reaching the
primary outcome increased by 17.7%. These results should, however, be treated with caution as only
31 out of 42 events have been included in this analysis as a result of missing data.
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FIGURE 5 Crohn’s Disease Endoscopic Index of severity score by study visit (visit 6 was 49 weeks post randomisation
and visit 12 was 157 weeks post randomisation). (a) Visit 6 and (b) visit 12. Mean CDEIS scores are indicated by a
diamond in the box plot. The minimum is indicated by the bottom of the lower whisker, the maximum is indicated
by the top of the upper whisker. The lower quartile is indicated by the horizontal line at the bottom of the box
and the upper quartile is indicated by the horizontal line at the top of the box. Outliers are shown as small circles,
identified as being 1.5 times outside the interquartile range. A higher CDEIS score indicates greater severity of
the disease.
TABLE 27 Visit 12 treatment effect for CDEIS score
Analysis type Visit 12 treatment effect
95% CI limit
p-valueLower Upper
Adjusted –0.612 –1.92 0.69 0.354
Unadjusted –0.661 –1.89 0.57 0.289
The adjusted analysis takes into account the stratification variables centre and smoking status, and also adjusts for previous
treatment with MP or azathioprine. The visit 12 treatment effect compares MP with placebo (reference). An effect of < 0
indicates a treatment effect in favour of MP.
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FIGURE 6 Mean change from baseline in faecal calprotectin level. Faecal calprotectin results of < 20µg/g faeces
have been included in the summary with a value of 0.
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Percentages are determined on non-missing data only.
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TABLE 28 Faecal calprotectin levels by colonoscopy result at visit 6
Colonoscopy result
Treatment
Overall (N= 240)MP (N= 128) Placebo (N= 112)
Negative (< i2) (n= 99, 47.6%)
Mean 98 181 133
Median 45 110 60
SD 148 243 197
Q1, Q3 20, 90 30, 180 20, 130
Min., max. 20, 810 20, 1080 20, 1080
n (missing) 44 (13) 33 (9) 77 (22)
Positive (≥ i2) (n= 57, 35.4%)
Mean 240 353 291
Median 170 220 170
SD 305 308 308
Q1, Q3 50, 260 120, 590 90, 350
Min., max. 20, 1200 20, 1130 20, 1200
n (missing) 27 (7) 22 (13) 49 (20)
max., maximum; min., minimum; Q1, quartile 1; Q3, quartile 3; SD, standard deviation.
TABLE 29 Faecal calprotectin levels by colonoscopy result at visit 12
Colonoscopy result
Treatment
Overall (N= 240)MP (N= 128) Placebo (N= 112)
Negative (< i2) (n= 99, 47.6%)
Mean 141 133 137
Median 45 70 60
SD 174 170 170
Q1, Q3 20, 260 20,200 20, 200
Min., max. 20, 660 20,750 20, 750
n (missing) 24 (14) 23 (6) 47 (20)
Positive (≥ i2) (n= 57, 35.4%)
Mean 146 262 200
Median 110 200 140
SD 143 203 181
Q1, Q3 50, 180 130, 270 80, 240
Min., max. 20, 530 30, 750 20, 750
n (missing) 22 (7) 19 (9) 41 (16)
max., maximum; min., minimum; Q1, quartile 1; Q3, quartile 3; SD, standard deviation.
i2: ≥ 5 aphthous lesions with normal mucosa between lesions, or skip areas of larger lesions or lesions confined to the
ileocolonic anastomosis.
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Secondary outcome: thioguanine nucleotide concentration levels
Thioguanine levels were summarised by time and treatment group both as a continuous measure and
categorically following independent blind review. Figure 8 shows the mean change from baseline in TGN
levels, with a slight and unexplained rise in TGN levels in the placebo arm. Figure 9 presents a categorical
summary of TGN levels in the MP group at each of the five time points measured throughout the trial.
In a similar manner to faecal calprotectin levels, TGN was assessed as a non-invasive marker of clinical
recurrence of CD by incorporating results from MP patients only as a time-varying covariate in the Cox
proportional hazards model. As shown in Table 31, the corresponding time-varying covariate analysis of
TGN concentrations (data available for 14 of the 16 patients receiving MP only) indicated that, for every
100-pmol/8 × 108 red blood cell increase in TGN, the hazard of reaching the primary out come decreased
by 20% (HR 0.800, 95% CI 0.565 to 1.132; p = 0.207).
Secondary outcome: changes in self-rated quality-of-life scores
Patient-reported outcome measures (as measured by IBDQ) were summarised at each visit based on
observed scores and change from baseline scores for each of the four IBDQ subscales (bowel symptoms,
emotional health, systemic systems and social function). Averages and totals across all subscales were
summarised similarly.
In addition, the overall average IBDQ score and overall total IBDQ score were statistically analysed using a
repeated measures analysis of covariance, modelling change from baseline, fitting terms for treatment, visit
and the interaction between treatment and time.
TABLE 30 Analysis of faecal calprotectin as a time-varying covariate (Cox proportional hazards model)
Model HR
95% CI limit
p> χ2 Number of primary eventsLower Upper
100-unit change
in calprotectin
1.177 1.082 1.282 0.0002 31
For each 100 µg/g increase in faecal calprotectin, the probability of reaching the primary outcome increases by 17.7%.
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FIGURE 8 Mean change from baseline in TGN levels. RBC, red blood cell.
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For both the overall average and overall total, there were no significant differences between treatment and
placebo groups across all study visits and the study overall. However, both treatment groups showed an
improvement in quality of life across all study visits in comparison with baseline, with the MP group
demonstrating the greater change across all visits. Figures 10 and 11 depict the results of the statistical
analysis for the overall average IBDQ and overall total IBDQ, respectively.
Safety outcomes
Adverse events
Of 1747 reported adverse events, 355 (20.3%) were infections, although only seven (0.4%) necessitated
hospitalisation, with higher rates in the group allocated to placebo. The majority of adverse events were
classed as either mild or moderate in severity [868 (91.6%) in the MP group and 728 (91.1%) in the
placebo group]. Adverse events caused discontinuation of treatment in 80 patients overall (33%): 39 of
the 128 (30%) patients in the MP group versus 41 of the 112 (36.6%) patients in the placebo group.
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FIGURE 9 Categorical summary of TGN levels (pmol/8 × 108 red blood cells). Percentages are determined on
non-missing data only. RBC, red blood cell.
TABLE 31 Analysis of TGN as a time-varying covariate (patients receiving MP only) (Cox proportional hazards model)
Model HR
95% CI limit
p> χ2
Number of primary
eventsLower Upper
100-pmol/8 × 108 red blood cells
change in TGN
0.800 0.565 1.132 0.207 14
For each 100-pmol/8 × 108 red blood cells increase in TGN, the probability of reaching the primary outcome decreased by
20.0%. Fourteen out of 16 events have been included in this analysis, based on those patients receiving MP only.
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Adverse events in the trial cohort overall are shown in Table 32, with serious adverse events in Table 33.
There were two cases of pancreatitis (0.1%, one in the MP group and one in the placebo group) and
four malignancies (0.2%, three in the MP group and one in the placebo group): basal cell carcinoma,
breast cancer and two cases of lentigo maligna. One participant died of coronary heart disease in the
placebo group.
Deaths
One death was recorded during the study period (coronary heart disease). This was in the placebo group
and was considered unrelated to the study intervention.
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FIGURE 10 Change from baseline final model treatment effects and 95% CIs for overall average IBDQ.
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FIGURE 11 Change from baseline final model treatment effects and 95% CIs for overall total IBDQ.
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Pregnancy
Of the 240 randomised patients, 14 pregnancies were reported (Table 34) during the course of the trial
[nine female patients (one of whom had two pregnancies) and in the partners of four male patients] with
12 normal children and maternal outcomes. We observed one spontaneous abortion at approximately
21 weeks’ gestation and one congenital anomaly (heart murmur, septal defect and hydrocephalus) in the
infant of a patient in the placebo group.
Safety blood monitoring
Blood safety monitoring tests of interest were summarised by treatment and visit. Abnormal laboratory
results outside the normal reference range were also summarised and are presented for each visit in
Table 35. The numbers highlighted in italics indicate a higher value than in the other treatment group.
TABLE 32 Summary of reported adverse events
Parameter
Treatment, n (%)
Overall (N= 240), n (%)MP (N= 128) Placebo (N= 112)
Had adverse event
Yes 121 (94.5) 105 (93.8) 226 (94.2)
No 7 (5.5) 7 (6.3) 14 (5.8)
Severity of worst event
Mild 14 (11.6) 8 (7.6) 22 (9.7)
Moderate 65 (53.7) 59 (56.2) 124 (54.9)
Severe 41 (33.9) 38 (36.2) 79 (35.0)
Missing 1 (0.8) 0 (0.0) 1 (0.4)
Total number of adverse events 948 799 1747
All adverse events split by category
Uncoded 1 (0.1) 1 (0.1) 2 (0.1)
GI symptoms: nausea/vomiting 78 (8.2) 41 (5.1) 119 (6.8)
GI symptoms: abdominal pain 132 (13.9) 141 (17.6) 273 (15.6)
GI symptoms: constipation/diarrhoea 54 (5.7) 56 (7.0) 110 (6.3)
GI symptoms: other 53 (5.6) 40 (5.0) 93 (5.3)
Worsening CD 41 (4.3) 37 (4.6) 78 (4.5)
Rash 35 (3.7) 17 (2.1) 52 (3.0)
Headache 61 (6.4) 38 (4.8) 99 (5.7)
Infections 171 (18.0) 184 (23.0) 355 (20.3)
Pain 30 (3.2) 19 (2.4) 49 (2.8)
Cancers 3 (0.3) 1 (0.1) 4 (0.2)
Deranged LFT 4 (0.4) 5 (0.6) 9 (0.5)
Pancreatitis 1 (0.1) 1 (0.1) 2 (0.1)
Joint pain/arthralgia 72 (7.6) 65 (8.1) 137 (7.8)
Other 212 (22.4) 153 (19.1) 365 (20.9)
GI, gastrointestinal; LFT, liver function test.
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TABLE 33 Summary of reported serious adverse events
System Organ Class (SOC1)
Treatment, number of
Overall, number ofMP Placebo
Patients Events
Related
events Patients Events
Related
events Patients Events
Related
events
Cardiac disorders 3 3 0 2 2 0 5 5 0
Congenital, familial and genetic disorders 0 0 0 1 1 1 1 1 1
Eye disorders 0 0 0 1 1 1 1 1 1
GI disorders 23 26 2 29 33 4 52 59 6
General disorders and administration site conditions 1 1 0 1 1 0 2 2 0
Hepatobiliary disorders 1 1 1 1 1 0 2 2 1
Infections and infestations 4 7 0 3 3 1 7 10 1
Injury, poisoning and procedural complications 1 1 0 1 1 0 2 2 0
Neoplasms benign, malignant and unspecified
(including cysts and polyps)
1 1 0 1 1 0 2 2 0
Nervous system disorders 0 0 0 1 1 0 1 1 0
Renal and urinary disorders 4 6 0 2 2 0 6 8 0
Reproductive system and breast disorders 2 2 0 0 0 0 2 2 0
Skin and subcutaneous tissue disorders 1 1 0 1 2 1 2 3 1
Surgical and medical procedures 9 9 0 5 5 0 14 14 0
Vascular disorders 1 1 0 0 0 0 1 1 0
Total 51 59 3 49 54 8 100 113 11
GI, gastrointestinal.
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TABLE 34 Reported pregnancies
Patient ID Centre Treatment Sex Estimated date of delivery Delivery date Maternal outcome Child outcome
11008 Edinburgh MP Malea 26 July 2009 Unknown Unknown Normal
11012 Edinburgh Placebo Malea 11 August 2010 21 August 2012 Normal Normal
11047 Edinburgh MP Female 12 November 2013 4 November 2013 Unknown Normal
11054 Edinburgh MP Female 17 June 2012 30 May 2012 Caesarean Normal
11067 Edinburgh MP Female 16 March 2012 5 March 2012 Caesarean Normal
11075 Edinburgh Placebo Female 29 March 2013 13 March 2013 Induced (IUGR) Normal
11075 Edinburgh Placebo Female 3 May 2014 7 April 2014 Normal Normal
12017 Aberdeen MP Female 22 April 2013 Unknown Abortion – spontaneous
5 October 2012
N/A
13024 Dundee Placebo Female 22 February 2012 22 February 2012 Normal Normal
14010 Glasgow Stobhill Placebo Female 15 October 2010 22 October 2010 Forceps/ventouse Normal
14024b Glasgow Stobhill MP Malea Unknown 28 September 2015 Normal Normal
15015 Glasgow Royal Infirmary MP Female 12 June 2013 31 May 2013 Normal Normal
18007 Liverpool Placebo Female 11 October 2012 26 September 2012 Normal Abnormal
34005 Durham MP Malea Unknown 3 December 2012 Normal Normal
ID, identifier; IUGR, intrauterine growth restriction; N/A, not applicable.
a Pregnancy in partner of male patient.
b Pregnancy reported following formal database lock.
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TABLE 35 Blood safety monitoring: % of out of range values by visit and treatment group
Visit
Blood safety monitoring test
ALT ALP Albumin C-reactive protein WBC count Haemoglobin Neutrophils Lymphocytes
MP Placebo MP Placebo MP Placebo MP Placebo MP Placebo MP Placebo MP Placebo MP Placebo
2 21.9 8 9 11.4 4.7 5.4 21.9 20.5 8.6 8.9 48.4 42.9 7.0 5.4 37.5 35.7
3 24.2 6.5 6.6 13.1 2.4 7.4 26.8 29.6 17.1 9.3 42.3 28.7 5.7 6.5 49.6 42.6
4 17.1 5.6 6.2 8.9 8.5 5.6 18.8 27.1 13.7 8.4 26.5 23.4 4.3 3.7 47.9 31.8
5 16.7 11.1 4.5 4.3 6.1 6.1 12.3 23.2 7.9 5.1 22.8 26.3 6.1 5.1 50.9 30.3
6 13.5 7.2 6.5 4.4 3.6 7.2 15.3 21.6 5.4 7.2 17.1 23.7 2.7 6.2 51.4 25.8
7 17.0 9.2 2.9 3.8 2.8 5.7 14.2 18.4 9.4 8.0 13.2 20.7 4.7 5.7 44.3 19.5
8 18.0 7.2 3.1 5.0 3.0 7.2 15.0 16.9 12.0 7.2 13.0 22.9 8.0 7.2 49.0 19.3
9 13.1 3.8 2.1 0.0 4.0 5.1 10.1 11.5 5.1 7.7 14.1 16.7 6.1 6.4 46.5 19.2
10 13.7 6.8 1.1 1.4 4.2 5.4 11.6 10.8 7.4 6.8 6.3 13.5 3.2 0.0 36.8 18.9
11 9.9 2.8 1.1 1.4 2.2 4.2 7.7 11.1 4.4 2.8 8.8 15.3 2.2 1.4 46.2 15.3
12 16.9 5.6 2.3 1.4 3.4 5.6 9.0 5.6 4.5 2.8 7.9 8.3 2.2 1.4 47.2 15.3
ALP, alkaline phosphatase; ALT, alanine aminotransferase; WBC, white blood cell.
The numbers in italics indicate a higher value than the other treatment group.
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Alanine aminotransferase and lymphocyte values were consistently higher across all visits in the MP group,
whereas the majority of C-reactive protein values were higher in the placebo group. Albumin and
haemoglobin values were higher in the placebo group from visits 6 and 5, respectively, until the end of
the trial.
Prespecified subgroup analyses of primary and secondary outcomes
Subgroup analyses of the primary and secondary outcomes (clinical recurrence of CD) were analysed
similarly to the main analysis of primary and secondary outcomes with the addition of an interaction term
for treatment and subgroup in the Cox proportional hazards model.
Primary outcome
The results show that, in the entire study cohort, smokers had a higher chance of reaching the primary
outcome than non-smokers [15/55 (27.3%) vs. 27/185 (14.6%); p = 0.018]. Among smokers, 3 out of 29
on MP (10.3%) had a clinical recurrence, compared with 12 out of 26 (46.2%) on placebo, demonstrating
that MP was effective at preventing postoperative recurrence in smokers (unadjusted HR 0.127, 95% CI
0.04 to 0.46) but not in non-smokers (unadjusted HR 0.898, 95% CI 0.42 to 1.94). The number needed to
treat was calculated as 3 in smokers and 31 in non-smokers. Other subgroup analyses assessing previous
TPMT exposure, prior methotrexate use, prior infliximab use, previous surgery and age at diagnosis did not
identify any differences between the groups.
Figure 12 shows the results of the overall unadjusted analysis of the primary outcome together with the
results of the individual subgroup analyses.
Secondary outcome
Clinical recurrence
Similar to the subgroup analyses of the primary outcome, subgroup analyses for the secondary outcome
demonstrated that smokers had a higher chance of reaching the secondary outcome than non-smokers
[19/55 (34.5%) vs. 55/185 (29.7%); p = 0.033]. Among smokers, 6 out of 29 on MP (20.7%) had a
secondary outcome, compared with 13 out of 26 (50.0%) on placebo, demonstrating that MP was
effective at preventing postoperative recurrence in smokers (unadjusted HR 0.270, 95% CI 0.10 to 0.72)
but not in non-smokers (unadjusted HR 0.995, 95% CI 0.58 to 1.70). There were no significant differences
in the analyses of the other subgroups. Figure 13 shows the results of the overall unadjusted analysis of
the secondary outcome together with the results of the individual subgroup analyses.
Endoscopic recurrence
There were no significant differences in endoscopic recurrence, as defined by the Rutgeerts score, by
treatment group on subgroup analyses except in the thiopurine-naive group (38 in the MP group vs. 29 in
the placebo group; p = 0.516).
Figures 14 and 15 show the results of the overall unadjusted analysis of visit 12 colonoscopy results and
CDEIS scores, together with the results of the individual subgroup analyses.
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Number of patients (%)
240 (100)
131 (54.6)
108 (45.0)
46 (19.2)
193 (80.4)
74 (30.8)
165 (68.8)
55 (22.9)
185 (77.1)
78 (32.5)
160 (66.7)
190 (79.2)
48 (20.0)
Number of patients (%)
experiencing outcomeHR (95% CI)
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16 (12.5)
12 (14.8)
4 (8.5)
4 (15.4)
12 (11.8)
7 (15.2)
9 (11.0)
3 (10.3)
13 (13.1)
3 (8.1)
13 (14.3)
15 (14.6)
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26 (23.2)
11 (22.0)
15 (24.6)
7 (35.0)
19 (20.6)
4 (14.3)
22 (26.5)
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14 (16.3)
11 (26.8)
15 (21.7)
19 (21.8)
7 (30.4)
p-value
0.046
0.336
0.995
0.236
0.018
0.220
0.115
Overall thiopurine status
Previous exposure
Naive
Previous treatment with infliximab/methotrexate
Yes
No
Previous surgery
Yes
No
Smoking status
Smoker
Non-smoker
Duration of disease (years)
< 1
> 1
Age at diagnosis (years)
< 40
> 40
0.01 0.1 1
Placebo betterMP better
10
FIGURE 12 Forest plot of primary outcome (unadjusted). The subgroup p-values are from a test for an interaction between the treatment and subgroup variables.
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Number of patients (%)
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34 (26.6)
23 (28.4)
11 (23.4)
6 (23.1)
28 (27.5)
13 (28.3)
21 (25.6)
6 (20.7)
28 (28.3)
9 (24.3)
25 (27.5)
28 (27.2)
6 (24.0)
Placebo
40 (35.7)
19 (38.0)
21 (34.4)
10 (50.0)
30 (33.0)
7 (25.0)
33 (39.8)
13 (50.0)
27 (31.4)
16 (39.0)
24 (34.8)
31 (35.6)
9 (39.1)
p-value
0.211
0.962
0.389
0.279
0.033
0.377
0.566
Overall thiopurine status
Previous exposure
Naive
Previous treatment with infliximab/methotrexate
Yes
No
Previous surgery
Yes
No
Smoking status
Smoker
Non-smoker
Duration of disease (years)
< 1
> 1
Age at diagnosis (years)
< 40
> 40
0.01 0.1 1
Placebo betterMP better
10
FIGURE 13 Forest plot of secondary outcome (unadjusted). The subgroup p-values are from a test for an interaction between the treatment and subgroup variables.
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FIGURE 14 Forest plot of colonoscopy results at visit 12 (unadjusted). The percentage of patients with a positive colonoscopy is based on positive (≥ i2) and negative (< i2)
colonoscopy results only. Missing and other colonoscopy results have been excluded. The subgroup p-values are from a test for an interaction between the treatment and
subgroup variables. i2: ≥ 5 aphthous lesions with normal mucosa between lesions, or skip areas of larger lesions or lesions confined to the ileocolonic anastomosis.
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FIGURE 15 Forest plot of CDEIS score at visit 12 (unadjusted). The subgroup p-values are from a test for an interaction between the treatment and subgroup variables.
D
O
I:10.3310/em
e04040
EFFICA
CY
A
N
D
M
ECH
A
N
ISM
EVA
LU
A
TIO
N
2017
VO
L.4
N
O
.4
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2017.
This
w
ork
w
as
produced
by
Satsangiet
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
45

Chapter 4 Discussion
Context
This study is the largest randomised, double-blind study in postoperative CD reported to date. In the study
cohort, analysed on an intention-to-treat basis, there is evidence of a reduction of clinical recurrence in
patients on MP compared with placebo, although this finding was not statistically significant. It is notable
that the treatment effect of 20% is lower than in previously conducted studies (Hanauer et al.:18 40%
reduction in mild CD lesions and 75% reduction in more severe lesions; Ardizzone et al.:19 25% reduction).
We judged a treatment effect of 20% appropriate because, given the side-effect profile of MP, it is
arguable that a treatment effect of significantly < 20% is of limited clinical significance.
Endoscopic recurrence is an important secondary outcome that other studies have prioritised over clinical
outcomes. No overall benefit of MP therapy on endoscopic outcome was identified in the present study
using the prespecified criteria of a Rutgeerts score of ≥ i2. However, on post hoc analysis, fewer patients
on placebo than on MP had endoscopically normal appearances at the anastomosis. The endoscopic
subgroup analysis showed an intriguing difference in treatment effect between thiopurine-naive and
non-naive groups, with patients previously exposed to thiopurine having greatest evidence of benefit.
The apparent discrepancy between clinical outcome measures and endoscopic outcomes is noteworthy.
There are several possible explanations for this, and clearly no consensus regarding whether or not to
prioritise clinical outcomes over endoscopic outcomes has emerged from previous trial data. The stringency
of our primary outcome and the internal correlation with faecal calprotectin assessment and with thiopurine
metabolite concentrations are arguments in favour of prioritising and relying on the clinical primary outcome.
Indeed, the validity and reproducibility of a Rutgeerts score of ≥ i2 – defined in the primary study from Rutgeerts
et al.,26 but not subject to detailed replication as a predictor of clinical recurrence – has been debated.
With respect to clinical practice, the data emerging from the trial strongly highlight the importance of
cigarette smoking in the pathogenesis and progression of CD, and as a target for therapeutic intervention.
Not only do the data show that the effect of MP on primary outcome was of statistical as well as clinical
significance in smokers, with a number needed to treat of only 3, but the analysis of factors predictive of
primary outcome is also noteworthy. Only smoking habit was predictive of outcome, whereas age, sex or
need for previous surgery were not implicated as risk factors for recurrence. The data underline the
importance of smoking cessation in disease management, and prioritising this aspect using all available
methodologies is of undeniable importance in clinical research. Previous studies have demonstrated that
surgical recurrence increases with the number of cigarettes smoked each day, and that smoking cessation
reduces clinical and surgical recurrence.32,33 To date, the constituents responsible in cigarette smoke, and
pathogenic mechanisms involved in this association, have not been identified.
Limitations
The present study does have a number of limitations. There was a lower primary event rate than initially
anticipated: the actual primary outcome rates in the treatment group were 12.5% in the MP group compared
with 23.2% in the placebo group as opposed to expected rates of 30% and 50%. Of the 240 patients
recruited into the study, 37 (15%) were also withdrawn or lost to follow-up. This compares favourably to the
rates reported in earlier trials.10,18,19,34 In the present study, 80 (33%) patients discontinued therapy as a result
of an adverse event [39 (30%) in the MP group vs. 41 (37%) in placebo group] and an additional 18 (8%)
patients withdrew as a result of an abnormal blood test result picked up on safety monitoring [12 (9.4%) in
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the MP group vs. 6 (5.4%) in the placebo group]. Ardizzone et al.19 reported treatment discontinuation rates
attributable to adverse events of 15 (10.7%) in the azathioprine group and 6 (4%) in the mesalazine group,
although figures on treatment discontinuation in other trials are more difficult to gauge from the published
figures.
The number of discontinuations does raise questions in terms of adherence in routine clinical practice and,
together with the numbers lost to follow-up, raises tantalising questions about the impact on the significance
of the primary analysis. In this sense, however, the present study may reflect the real-life use of thiopurines
in a postoperative population. We would argue that this trial has considerable value as a pragmatic trial in
which the results and experiences of participating patients are highly generalisable to the clinic population
seen not only in the UK but in much of Western Europe and North America.
Another limitation was the number of missing values in the analysis of the secondary outcomes, which
could affect the overall results. However, the proportion of missing values between treatment groups was
assessed and found to be similar.
There were no worrying signals with respect to adverse events in the present study. Indeed, lower than
expected rates of pancreatitis and malignancies were reported. Fourteen pregnancies were reported, with
12 healthy births, one miscarriage and one abnormal birth to a mother in the placebo group. The stringent
precautions for blood monitoring may well be pertinent to the safety profile demonstrated in the trial.
Strengths
The strengths of this study include the placebo arm, the assessment of both clinical and endoscopic
outcomes, dose adjustment by TPMT status, the stringency of the primary end point and the attention to
maintenance of blinding throughout, as well as its generalisability to routine clinical practice.
A further issue worthy of discussion and of exploration in further studies is whether or not a stronger
treatment effect would have been seen if the TPMT metabolite profiles were available for dose adjustment
during the trial, as is now routine in clinical practice. The data presented suggest that a significant
proportion of patients may have benefited from higher doses of active drug; indeed, almost 60% had
levels below the accepted lower limit of the therapeutic range.
Applicability in UK hospitals and beyond
The study population and the overall findings of the study are highly generalisable in clinical practice in the
UK and indeed across Western Europe and North America.
Taken with other recent data from the POCER study investigators,13 the present study helps make progress
towards a treatment algorithm in postoperative CD that may prove to be generalisable in clinical practice.
We suggest that cessation of cigarette smoking emerges as the key intervention to emphasise ahead of
drug therapy. In those who continue to smoke, but not non-smokers, thiopurine therapy appears to be
justified in the early postoperative period, and we would now suggest the need to explore dose optimisation
by metabolite testing. In thiopurine-intolerant patients, anti-TNF-α therapy may be justified. In all patients,
reassessment of clinical status, endoscopic appearances and calprotectin levels in 6 months will determine
need for escalation of therapy.
DISCUSSION
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Reducing variance in clinical practice
The present study provides useful insights by identifying size of effect of thiopurine therapy overall, and
the subgroup in which it is most effective. The identification of smoking habit as the key risk factor for
recurrence is also of considerable importance in practice.
All these represent important points generalisable to clinical practice and intervention.
The present data are suggestive of utility of calprotectin levels in predicting clinical recurrence, and utility
of metabolites in optimising thiopurine therapy. These data will need to be explored in further studies but
both represent potential biomarkers that may help optimise intervention.
Potential risks not explored in this study
The study had a 3-year treatment period but did not have a follow-up period for recruited patients.
The longer-term management of this patient population and the duration of therapy remain unexplored.
Unanticipated findings
The magnitude of effect of smoking habit on primary outcome was unexpected, and represents a
key finding.
Patient public involvement
Patient public involvement in TOPPIC was limited. A lay representative formed part of the TSC and, as
such, was invited to all formal meetings and provided with the TSC reports and updates with the initial
meetings attended.
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Chapter 5 Conclusions
Implications for health care
TOPPIC was designed in 2003–4 and completed in 2015 as the largest single study of the efficacy of MP in
reducing postoperative recurrence in CD. This has since remained an important question in the context of
disease management over time, although the introduction of new biological therapies and the widespread
use of biomarkers and therapeutic drug monitoring need to be taken into account in assessing current
impact and implications.
We have defined the rate of clinical and endoscopic disease recurrence in the UK population, and
have characterised the key risk factor amenable to public health intervention as smoking, while also
demonstrating that other proposed risk factors do not have a significant effect in this study. The last
finding is not to be underestimated – age, disease behaviour and previous exposure to thiopurines do not
appear to influence outcome adversely.
From the clinical perspective, the need to educate and re-educate patients and clinicians regarding the
deleterious effects of smoking on outcome is critical, as is the need to put in place all available strategies
to help with smoking cessation.
From the trial itself, MP was not effective in reducing the frequency of clinical postoperative recurrence
of CD overall, but the data suggest that it has clinically meaningful effect among the subgroup of patients
who continue to smoke after surgery. Importantly, with the benefit of the results of therapeutic drug
monitoring of TPMT levels available after the trial, it appears that many patients were underdosed per
protocol, and the data generated in the trial may underestimate the potential benefit in the clinic.
Taking these data in the context of other published data in this field, we suggest that risk stratification
of relapse after surgery is principally influenced by smoking habit, and would offer prophylaxis with
thiopurine therapy to those individuals who continue to smoke, if the drug is tolerated. In all patients,
these data, and the data from the POCER study, make the case for monitoring faecal calprotectin levels
and offering endoscopic assessment within 6–12 months of surgery to those with elevated calprotectin
values, or clinical concern of recurrence. At this stage, the introduction of thiopurine therapy or biological
therapy needs to be assessed in terms of the presence or absence of symptoms, and endoscopic features.
Recommendations for research
A number of areas in which further research is required emerge from the present study.
l Although the present study defines the role of MP in postoperative prevention, we also provide
evidence that the effect might be underestimated in the present study.
l A further trial designed to incorporate concomitant real-time measurements of faecal calprotectin
levels, TPMT metabolites and other biomarkers in the clinic, and using the combination of these
parameters to optimise and target therapy on appropriate individuals, is likely to provide a more
accurate estimate of the full therapeutic potential of thiopurines in the postoperative setting.
l Most importantly, there is a research need to explore the efficacy of other agents as monotherapy or
co-therapy with thiopurines – anti-TNF-α therapies, vedolizumab and ustekinumab will all be available
in this context in 2017, with other new oral agents in advanced stages of analysis. This area is likely to
require specific trials, incorporating the understanding generated in the present study.
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l The trial has also demonstrated the need for research to identify the optimum biologically meaningful
outcome measure in studies of postoperative recurrence, with discrepancies between the results when
clinical, biochemical and endoscopic end points are considered.
l With TOPPIC strongly highlighting the effect of smoking on recurrence rates, the data demonstrate the
need for directed intervention studies to assess the relative success of alternative strategies in smoking
cessation in patients with CD.
l The trial also highlights the need for mechanistic studies to explore the very well-documented
association between smoking and development, with epigenetic, immune-mediated mechanisms
currently of particular interest.
l Exploration of efficacy of other agents in preventing postoperative relapse – these will include
anti-TNF-α therapies and anti-adhesion strategies.
CONCLUSIONS
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